Entities

Nathan Demazel is publicly listed by Ouest Valorisation as Ingénieur R&D Assemblage et formage des métaux. This is the institution’s named professional affiliation in technology transfer and innovation support.

Anaïs Daguet is publicly listed by Ouest Valorisation as Assistante - Chargée de mission qualité. This is the institution’s named professional affiliation in technology transfer and innovation support.

Carole Boissière is publicly listed by Ouest Valorisation as Chargée d'affaires partenariat. This is the institution’s named professional affiliation in technology transfer and innovation support.

Catherine Brunel is publicly listed by Ouest Valorisation as Assistante Direction des Relations Partenariales. This is the institution’s named professional affiliation in technology transfer and innovation support.

Cédric Caro is publicly listed by Ouest Valorisation as Chargé d'affaires Partenariat. This is the institution’s named professional affiliation in technology transfer and innovation support.

Christine De Oliveira is publicly listed by Ouest Valorisation as Attachée de direction. This is the institution’s named professional affiliation in technology transfer and innovation support.

Dalyal Copin is publicly listed by Ouest Valorisation as Ingénieur R&D Impacts environnementaux. This is the institution’s named professional affiliation in technology transfer and innovation support.

Flora Bordis is publicly listed by Ouest Valorisation as Juriste. This is the institution’s named professional affiliation in technology transfer and innovation support.

Gaële Couëtuhan is publicly listed by Ouest Valorisation as Assistante Achats. This is the institution’s named professional affiliation in technology transfer and innovation support.

Sandra Claveau is publicly listed by Ouest Valorisation as Chef de projet entrepreneuriat PUI. This is the institution’s named professional affiliation in technology transfer and innovation support.

Sigolène Canaguier is publicly listed by Ouest Valorisation as Cheffe de projets thématiques. This is the institution’s named professional affiliation in technology transfer and innovation support.

SATT Ouest Valorisation is the French technology-transfer and research-commercialisation company serving public laboratories in Brittany and Pays de la Loire. Founded in2012, the SAS is identified by own legal notices with SIREN753000611 and a Rennes headquarters. It detects and protects scientific inventions, finances technical and economic maturation, negotiates research partnerships and technology licences, and supports creation of deeptech start-ups. Its OneHealth and Advanced Sustainable Technologies units span biotechnology, devices, medical research, materials and engineering. This is a corporate technology-transfer institution and occasional direct shareholder, not an inferred private venture-fund manager. The current own directory publishes73 named professionals, including ten leadership biographies; Franck Teston has been president since October1,2025. The university shareholder pact holds50% and currently comprises11 institutions; these governance affiliations do not establish a duplicate university cash buyer. The French research ministry identifies an original EUR70M State allocation under the Programme d’Investissements d’Avenir; this maturation allocation and statutory share capital are not external LP fund closes. No independently verified pooled investment-fund corpus is assigned. Primary September2020 materials confirm entry into GlioCure’s share capital following earlier patent protection, maturation and technology transfer; share price, instrument and cash paid are undisclosed, and maturation spending is not assumed to be the later equity check. Its wider start-up directory shows supported research spin-outs, not proof that every recipient received a direct equity investment. Current own legal name and brand are distinct from other regional SATT institutions and Ouest venture managers.

Baptiste Clair leads entrepreneurship at Ouest Valorisation and sits on its executive committee. An ESSEC graduate, he worked in technology investment banking at Jefferies and nearlyeightyears at Clipperton, then co-founded and led Demain Works in2022. He supports the creation and development of research spin-outs.

Benjamin Trinel leads the Advanced Sustainable Technologies business unit and sits on Ouest Valorisation’s executive committee. A materials engineer trained at ENSIL, he spent15years in Setec’s materials research organisation, progressing through engineering and business roles to leadership of its Rennes office.

Camille Thomas leads the academic-contracts business unit and belongs to Ouest Valorisation’s executive committee. Her background combines molecular biology, knowledge management and innovation management. Following experience at CEA and almosteightyears in R&D partnerships at Inserm Transfert, she joined Ouest Valorisation as a business-development professional in2018.

Candice Lamoureux leads marketing and communications and belongs to Ouest Valorisation’s executive committee. An agrofood engineer trained in formulation and innovation, she joined in2020, initially working on agri-food projects and marketing. She took responsibility for marketing and communications inJanuary2024 after experience in food and medical devices.

Clémence Ackaouy Busson is publicly listed by Ouest Valorisation as Chargée de mission entrepreneuriat. This is the institution’s named professional affiliation in technology transfer and innovation support.

Cyrille Chapon directs innovative projects and technology transfer at Ouest Valorisation and sits on its management committee. His technology-transfer career began in1998 and includes university-industry liaison at Reims, research valorisation at Rennes1 and deputy leadership at Bretagne Valorisation. He oversees maturation and transfer of technologies from regional laboratories.

Franck Teston has served as President of SATT Ouest Valorisation since October1,2025. He joined in2013 as research-partnership director after leading industrial and commercial research activities and university partnerships at Tours. His career focuses on connecting public laboratories with company innovation needs.

Laurent Crémillieux is listed by Linksium as an independent investment-committee expert. The directory describes the external professional background as Directeur des Partenariats Europe, Schneider Electric.. This is a committee affiliation, not Linksium employment or a statutory-director role.

Maxime Bigot is publicly listed by Ouest Valorisation as Responsable SI. This is the institution’s named professional affiliation in technology transfer and innovation support.

Romain Bévan is publicly listed by Ouest Valorisation as Responsable Fabrication Additive et Prestations pour l’UBS. This is the institution’s named professional affiliation in technology transfer and innovation support.

Romain Labas leads Ouest Valorisation’s OneHealth business unit and belongs to its executive committee. A chemistry engineer and doctorate holder, he worked in diagnostic and therapeutic R&D at CEA and InCellArt, followed by16years in international medtech marketing at The MarkeTech Group. He now supports licensing and technology transfer across human, animal and plant health.

Solen Charlou leads Ouest Valorisation’s legal business unit and sits on its executive committee. She trained in intellectual property and intangible-asset valorisation at CEIPI in Strasbourg. Her published career includes nearlytenyears in industry and technology innovation, with expertise in complex contracts, intellectual-property protection and regulatory compliance.

Tara Duong joined Ouest Valorisation inOctober2025 as research-partnership director and management-committee member, following leadership of AP-HP’s technology-transfer and intellectual-property office. He has master’s training in biochemistry and management and consulting experience in life sciences, energy and information technology.

Valérie Pelletier is Ouest Valorisation’s director of financial affairs and management-committee member. Her published biography describes more than30years in administration, finance and management across varied organisations, including work supporting local public-sector actors since2014.

Vincent Deltrieu is listed by Linksium as an independent investment-committee expert. The directory describes the external professional background as Managing partner, Yotta Capital. This is a committee affiliation, not Linksium employment or a statutory-director role.

Xavier Basnier is publicly listed by Ouest Valorisation as Technicien d’essais. This is the institution’s named professional affiliation in technology transfer and innovation support.

Noémie Ballot is listed by Linksium as an independent investment-committee expert. The directory describes the external professional background as Corporate Business Incubator Manager, Soitec. This is a committee affiliation, not Linksium employment or a statutory-director role.

Olivier Cateura is listed by Linksium as an independent investment-committee expert. The directory describes the external professional background as Professeur, EM Lyon. This is a committee affiliation, not Linksium employment or a statutory-director role.

Odile Allard is listed by Linksium as an independent investment-committee expert. The directory describes the external professional background as CEO, Ex FLuoptics. This is a committee affiliation, not Linksium employment or a statutory-director role.

One Giant Leap Ventures is Rice University’s early-stage venture investment platform supporting startups founded or led by Rice alumni, students or faculty, and companies commercializing Rice-licensed intellectual property. It invests across industries through a rules-based process requiring Rice affiliation and a qualified outside lead investor before Investment Advisory Committee review. The platform combines university and limited-partner participation with access to Rice’s alumni network for diligence, mentoring and commercialization support. Its first disclosed investment is Motif Neurotech, which develops an investigational minimally invasive neurostimulator for treatment-resistant depression. The mandate spans Rice-affiliated businesses broadly rather than being an exclusively neuroscience fund.

Rice undergraduate and Rice Innovation Venture Scholar, listed in One Giant Leap’s current Venture Scholars group.

Rice alumnus and startup founder leading One Giant Leap Ventures. Rice also identifies his separate university role as interim vice president for innovation and chief innovation officer; this outside university title is not assigned as a fund office.

Rice MBA class of 2027, Rice Innovation Venture Scholar, Rice Business Student Association president and Consortium Fellow, as published by the fund.

Rice Innovation Venture Scholar and PhD candidate in bioengineering. The fund publishes her in its current Venture Scholars group; this is an educational affiliation rather than inferred employment.

Christine Vaca serves in Linksium’s published Directrice du Pôle Expertises function. She connects scientific teams, entrepreneurs and technologies in the Alpine ecosystem.

One Giant Leap Venture Scholar alumna. Its own card identifies her as a University of Texas at Austin undergraduate in economics and philosophy and a Yale Young Global Scholars alumna; no Rice student status or current fund job inferred.

CEO and founder of Steer Bio and a lymphatic disease advocate with a bioengineering background, as described by One Giant Leap. Published in its Venture Scholar Alumni group; outside startup role is biographical context.

Rice alumna serving as investment manager of One Giant Leap Ventures. Its own team page separately identifies her as senior innovation manager in Rice’s Office of Innovation.

Founder of NIVERA and NSF Graduate Research Fellowship PhD fellow in materials science and nanoengineering associated with Rice’s Preston Innovation Lab. One Giant Leap lists her in its Venture Scholar Alumni group; current fund employment is not implied.

Véronique Souverain serves in Linksium’s published Pôle Expertises function. She helps deep-technology projects explain their distinctive value and develop communication strategies.

Evelyne Sergeant serves in Linksium’s published Pôle Pilotage Gestion et Achats function. She handles administrative and financial monitoring of research-maturation project expenses.

Gisela Schach serves in Linksium’s published Pôle Opérations et Transfert function. She describes engineering training and15 years of international experience and helps translate research into startup or industrial opportunities.

Perrine Scapaticci serves in Linksium’s published Pôle Opérations et Transfert function. The current directory identifies this operating affiliation; additional career and education details are not publicly provided there.

Christophe Poyet serves in Linksium’s published Pôle Expertises function. He describes professional-coaching and R&D leadership experience; he supports digital projects with market analysis, intellectual property and founder development.

Sarah Renaud serves in Linksium’s published Chargée de développement RH function. The current directory identifies this operating affiliation; additional career and education details are not publicly provided there.

Chloé Poyet serves in Linksium’s published Pôle Opérations et Transfert function. The current directory identifies this operating affiliation; additional career and education details are not publicly provided there.

Pierre-Yves Perche serves in Linksium’s published Pôle Expertises function. He helps teams structure business plans, funding needs and startup formation.

Stéphan Pédèche serves in Linksium’s published Pôle Emergence function. He describes a doctorate and engineering background with international research-and-development experience, supporting emerging technology ventures.

Valentine Panel serves in Linksium’s published Pôle Expertises function. Her published background includes a biology doctorate and technology-transfer training in the United States; she supports healthcare projects through scientific, market and regulatory development.

Luc Oba serves in Linksium’s published Pôle Expertises function. He helps assemble deep-technology founding teams and investigate potential markets.

Christine Melay serves in Linksium’s published Pôle Opérations et Transfert function. She helps research teams negotiate industrial licensing and promotes technology-transfer projects.

Hélène Marty serves in Linksium’s published Directrice Pôle Pilotage Gestion et Achats function. The current directory identifies this operating affiliation; additional career and education details are not publicly provided there.

Alice Léonard serves in Linksium’s published Pôle Emergence function. The current directory identifies this operating affiliation; additional career and education details are not publicly provided there.

Thibault Larrasa serves in Linksium’s published Pôle Opérations et Transfert function. The current directory identifies this operating affiliation; additional career and education details are not publicly provided there.

Géraldine Lancel serves in Linksium’s published Pôle Business & Equity function. The current directory identifies this operating affiliation; additional career and education details are not publicly provided there.

Yves Hemery serves in Linksium’s published Pôle Business & Equity function. He coordinates startup acceleration and describes experience supporting more than200 startups.

Mathieu Guerre-Chaley serves in Linksium’s published Pôle Gouvernance et Relations Institutionnelles et Données function. He supports IT systems and develops project databases and reporting dashboards.

Marie Grollier serves in Linksium’s published Pôle Pilotage Gestion et Achats function. She tracks incubation contracts and project finances under governance decisions.

Anne-Lucie Grange serves in Linksium’s published Directrice du Pôle Gouvernance et Relations Institutionnelles et Données function. She coordinates governance, shareholder relations, institutional partnerships, European matters and corporate communication.

Jean-Philippe Gendre serves in Linksium’s published Directeur du Pôle Business & Equity function. The current directory identifies this operating affiliation; additional career and education details are not publicly provided there.

Lamria Dehil serves in Linksium’s published Pôle Pilotage Gestion et Achats function. Her published work covers project logistics, welcoming participants and maintaining communication materials.

Murielle Bredillard serves in Linksium’s published Training Center function. She develops entrepreneurial training for deep-technology founders and identifies early startup projects.

Sophie Clerc serves in Linksium’s published Pôle Pilotage Gestion et Achats function. The current directory identifies this operating affiliation; additional career and education details are not publicly provided there.

Sri Nathalie Fabre serves in Linksium’s published Pôle Opérations et Transfert function. She supports intellectual-property protection and assembles transferable portfolios of research assets.

Manel Boumegoura serves in Linksium’s published Directrice Pôle Emergence function. She helps researchers and postdoctoral teams design technology-transfer projects with institutional partners.

Catherine Lafarge is Linksium’s currently published president. Linksium announced her appointment as interim president on July18,2025; a permanent appointment and exact employment start day have not been verified.

SATT Linksium Grenoble Alpes is a French technology-transfer and startup-building company established in July 2014. Its own legal notice identifies a SAS, SIREN803938372 (VAT FR47803938372), with nominal share capital of EUR1 million and headquarters in Grenoble. It is a private company with public capital, rather than an independent limited-partner venture fund. Published shareholders include Bpifrance, CEA, CNRS, Grenoble INP-UGA, INRIA, Université Grenoble Alpes and Université Savoie Mont Blanc. Linksium develops public-research inventions through technology maturation, intellectual-property protection, industrial licensing, startup incubation and business/equity support. Relevant projects include HuntX Pharma’s preclinical axonal-transport research for Huntington disease, Emoface’s digital emotion-learning tools and industrial deep-technology ventures such as biofuel-cell developer BeFC. Incubation or fundraising assistance alone does not establish a cash investment in a named priced round. The HuntX issuer explicitly describes Linksium as a historical shareholder separately from the September2024 EUR1.7 million financing buyers. The current public directory names 28 operating people. Catherine Lafarge is currently listed as president; the own July18,2025 announcement appointed her president on an interim basis and no permanent-appointment date is assumed. A separate investment committee comprises 13 independent industrial, financial and entrepreneurial experts; these are external committee members, not employees or statutory directors by inference. The current French ecosystem page reports a EUR70 million State commitment over ten years, while the English version reports EUR57 million. Both published values are retained as differing versions of a public programme commitment, not an actual LP fund close. Current homepage metrics include 98 startups,247 technology-transfer projects and EUR66 million cumulative project investment; these are programme activity metrics, not new fundraising or individually allocated cash checks. French Tech Seed introductions concern a separate Bpifrance programme. No standalone Linksium LP fund or exact institutional fundraising close has been verified.

Grenoble Angels is the Isère association of business angels, founded in2005 and affiliated with the national France Angels federation. Its own legal notice identifies SIREN492569371 and headquarters at5–7PlaceRobertSchuman,Grenoble. It is a nonprofit member-investor network, rather than a verified conventional pooled-LP venture manager. Members provide private capital, operating expertise and business connections to innovative early-stage companies. The own FAQ explicitly says members decide their individual investments and subscribe directly; typical ticket ranges and network deployment aggregates are not association balance-sheet cash or fund closings. Current primary sources identify president PhilippeRase, re-elected for2026–2028, and a2025 operational team comprising Anne-SophieVernay, TanguyBattistella and RyanAtie. GrenobleINP’s updatedJune2026 governance corroborates Anne-Sophie’s director role. The latest accessible own governance report explicitly labels its roster2024/2025, while ownAugust2026 andMay2026 report posts have missing report links. Accordingly,22 additional governance and operational affiliations are documented with dated labels rather than asserted wholesale as current2026staff; former general delegate JonathanCollomb is qualified as replaced after the2024 issuer announcement. AlexandreConroy is separately named by HuntX as a2024 network business angel evaluating the neurotechnology company, without an inferred personal check. The full available named profile comprises27 unique people and roles, with26 authentic source-bound portraits and one unpublished-portrait gap. Deep-technology relevance is explicit: half the2025 funded startups are described by the federation as deeptech, alongside medtech and innovative software. Members invested more than EUR1M in20companies in2025 and EUR3M over2023–2025; these are network activity aggregates, not new funds. No verified external-LP fund close is published. GrenobleAngelsParticipations2SAS is a separately registered vehicle; its membership, assets and subscribing role in any specific issuer round require deal-specific proof and are not silently substituted for the association. HuntX’s September2024 EUR1.7M financing names the network alongside other angel networks and patient families. The institutional relationship represents member-network backing, with exact underlying subscribers, network allocation and association treasury participation unpublished.

Alain Roche is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Alexandre Conroy is named in HuntX Pharma’s September2024 issuer financing announcement as a business angel evaluating the neurotechnology investment. The source identifies a network-member affiliation, rather than an association employee or proven personal cash ticket. Exact broader current role and company allocation are unpublished.

Andrea Battistella is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Andrew Slipper is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Anne Bagard is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Anne-Sophie Vernay is publicly affiliated with Grenoble Angels. France Angels identifies Anne-Sophie as general delegate from April2025; current June2026 Grenoble INP governance identifies her as Grenoble Angels director. She leads the association’s operations and ecosystem relationships. The ownpublicprimary sources do not establish any personal company subscription.

Antoine Sandanassamy is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Cheikhou Dieye is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Honorary Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Coralie Annee is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Project Lead, Dealflow (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Fouad Teban is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Frédéric Simoës is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Isabelle Marouard is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Honorary Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Jean Chabbal is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure. Jean Chabbal is listed by Linksium as an independent investment-committee expert. The directory describes the external professional background as Expert Senior, Ex-Directeur Général, Trixell. This is a committee affiliation, not Linksium employment or a statutory-director role.

Jean-Louis Brunet is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The own network’s founder is published as honorary president. The report explicitly publishes the role as Founder; Honorary President (2024/25 report). The original report portrait is a dated source image rather than proof of current tenure.

Jean-Marc Govers is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Jean-Philippe Bourille is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board affiliation, SAMBA representative (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Jean-Yves Costa is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Jonathan Collomb was Grenoble Angels general delegate in the own2024 report and HuntXSeptember2024 issuer release. France Angels identifies Anne-SophieVernay as general delegate fromApril2025, so his executive affiliation is historical. The original dated report portrait is preserved; no personal check is inferred.

Michel Cezon is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Olivier Gau is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Olivier Seite is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board affiliation, RVA representative (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Philippe Martinelli is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Philippe Rase is publicly affiliated with Grenoble Angels. Current own homepage and federation February2026 announcement verify re-election. He is publicly identified as a business angel and co-president of France Angels. The association supports innovative early-stage ventures through member capital, expertise and networks. No individual company check is inferred.

Rodrigue Le Gall is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Ryan Atie is publicly affiliated with Grenoble Angels. France Angels identifies Ryan as the apprenticeship-based assistant dealflow manager joining in2025. He supports startup sourcing, investment-file analysis and transaction coordination with Tanguy Battistella. An exact current appointment end date and a personal company subscription are unpublished.

Sylvian Kaiser is named in Grenoble Angels’ own report, on its governance and operational page headed 2024/2025. The source documents the published association affiliation at that time; exact current tenure, broader career and individual company allocations are not established. The report explicitly publishes the role as Board Member (2024/25 report; current tenure unconfirmed). The original report portrait is a dated source image rather than proof of current tenure.

Tanguy Battistella is publicly affiliated with Grenoble Angels. France Angels names Tanguy as the dealflow manager appointed in2025, following SAMBA, Evolem and UI Investissement experience. Responsibilities include startup sourcing, investment-file analysis and transaction coordination with the board and working groups.

Co-founder and managing director of Mountain Group Partners, focused on disruptive technologies. Previously served as executive vice president and chief marketing officer at Asurion and held senior management roles at Excite@Home and Verizon. Began his career in brand management and advertising at Procter & Gamble and PepsiCo; earned an MBA at the University of Chicago.

Associate at Mountain Group Partners, which he joined in 2024, evaluating investment opportunities and advising portfolio companies on financial, operational and strategic initiatives. Previously worked in services and industrials investment banking at Piper Sandler. Earned a BS in accounting and finance at the University of South Carolina.

Director at Mountain Group Partners, which he joined in 2022. Leads investor relations and advises portfolio companies on financial, operational and strategic initiatives. Previously worked in debt capital markets at J.P. Morgan and in the risk division at Goldman Sachs. Earned a BA in economics at Vanderbilt University.

Principal at Mountain Group Partners, which he joined in 2019, focusing predominantly on healthcare technology. Previously worked in investment banking at Raymond James, Brookline Capital Markets and Stephens. Earned undergraduate and graduate accounting degrees at the University of Mississippi. The firm describes portfolio-board service or visitation rights without distinguishing the status of each company; these are not converted into individual directorships.

Co-founder and managing director of Mountain Group Partners, focused on drug development and diagnostics. Retired as group vice president for global operations at Eli Lilly in 1993 after more than 28 years with the company. Previously served as Amylin chief executive and chairman and was an Ironwood founder and chairman. Mountain Group currently identifies him as executive chairman of Appello Pharmaceuticals. Earned an engineering degree at the University of Tennessee.

Associate at Mountain Group Partners, which he joined in 2025, evaluating investment opportunities and advising portfolio companies on financial, operational and strategic initiatives. Previously served as actuarial lead analyst at Cigna, working on healthcare affordability and specialty-pharmacy economics, and earned the Associate of the Society of Actuaries credential. Earned a BA in mathematics and economics at Vanderbilt University.

Managing director of Mountain Group Partners, focused on animal health and drug development. Spent nearly 30 years at Elanco Animal Health in senior management roles overseeing research and development and the commercialization of animal-health products. Earned a PhD in analytical chemistry at the University of Illinois.

Director at Mountain Group Partners with more than 20 years of animal-health product discovery, development, acquisition and registration experience. Previously led research and development, regulatory and external innovation efforts at United Animal Health and held development roles at Elanco. Earned an undergraduate degree at the University of Wisconsin and a PhD in analytical chemistry at Miami University. His current Director title supersedes the Venture Partner title in his November2022 appointment announcement.

Carl Simonsson is a chemist specializing in colloidal systems, formulations and biopharmaceutical development. GlioCure appointed him to lead its Cure’nCaps Solutions business unit in May2021. His published background included Carlina Technologies R&D project leadership2017–2020, nanomedicine research at the University of Angers and teaching organic/pharmaceutical chemistry at Gothenburg. This is a GlioCure business-unit affiliation, not a separately created company or verified current tenure.

Clément Sanchez is named by GlioCure as a research engineer in its November3,2023 neuro-oncology research-support announcement and as a member of its team in February/March2025 donation photographs. The company’s caption establishes his specific affiliation, distinct from unrelated chemist homonyms. A fuller career biography and an individual authentic headshot were not publicly verified; no group-photo substitute is attached.

Olivier Meyer is a pharmaceutical scientist and biotechnology entrepreneur with lipid-nanovector and drug-delivery experience. GlioCure announced him as Vice-President Corporate Development in May2021 alongside its nanovector business expansion. His reported career included UCSF postdoctoral research, Transgene, AstraZeneca, Bioxalis Medica, Bioxel Pharma and founding Carlina Technologies. The role is historically sourced, not an assertion of current2026 tenure.

Sandrine Courtès is a biomedical researcher and entrepreneur with a neuroscience doctorate, molecular-cellular-oncology training at ENSLyon and experience in small-animal pharmacology, oncology and strategic research management. GlioCure announced her appointment as Director of Preclinical Development and Intellectual Property effectiveJuly1,2021. Her background included Scripps postdoctoral research and neuro-oncology development at Coral Biome Pharma. This is a dated appointment; the current public three-person management directory does not establish her continuing tenure.

Joël Eyer is an Inserm research director and neuroscience researcher specializing in neuronal cytoskeleton, peptides and glioblastoma. He co-founded GlioCure in September2016 with Claire Lépinoux-Chambaud and Louis-Marie Bachelot; his research team discovered the NFL-TBS.40-63 peptide underlying GC01. Own2017 and2020 announcements named him a scientific adviser, while the current public advisory directory names four other experts. Founding and historical advisory affiliations are retained without inventing current employee status.

Le Dr. Emeline Tabouret, est Maitre de Conférences des Universités – Praticien Hospitalier au sein du Service de Neuro-Oncologie du Prof. Olivier Chinot à l’Hôpital de la Timone (APHM) et enseignant-chercheur, titulaire d’une Habilitation à Diriger des Recherches, à l’Institut de Neurophysiopathologie de Marseille, UMR7051, équipe 8, dirigée par le Prof. Figarella-Branger. Très impliquée dans la vie associative et les sociétés savantes de son domaine d’expertise, le Dr. Tabouret est notamment membre du Conseil National des Universités (CNU) de Cancérologie – Radiothérapie, du groupe Tumeurs du Cerveau à l'Organisation Européenne pour la Recherche et le Traitement du Cancer (EORTC), et du comité scientifique du Cancéropole PACA. Elle a également été Secrétaire Générale Adjointe, de 2015 à 2018, puis Secrétaire Générale, de 2018 à 2021, de l’Association des Neuro-Oncologues d’Expression Françaises (ANOCEF). Auteur de plus de soixante-dix publications scientifiques et médicales et co-inventeur de deux familles de brevets, elle a reçu de nombreux prix et obtenus près d’un million d’euros de financements pour ses travaux de recherche hospitalo-académiques. Dans le cadre de ces activités, Emeline Tabouret s’intéresse en particulier au rôle biologique de certaines molécules – les métalloprotéinases – dans le développement des gliomes et dans la résistance aux thérapies anti-angiogéniques. Le Dr Emeline Tabouret est dipômé de médecine et docteur en sciences de la Faculté de médecine de Marseille.

Le Dr. Joël Richard, expert en physico-chimie et R&D Biopharmaceutique, est Chef des opérations techniques et pharmaceutiques de MedinCell. Précédemment, Joël Richard était Vice-Président Senior Développement Peptides d'Ipsen en charge de la supervision de toutes les activités de développement pharmaceutique et de production des lots cliniques des peptides et petites molécules du groupe pharmaceutique au niveau mondial. Le Dr Joël Richard était également Directeur Général d'OctreoPharm Sciences GmbH, une filiale du groupe Ipsen spécialisée dans les produits radiopharmaceutiques pour le diagnostic et le traitement des cancers. Avant cela, Joël Richard a été Directeur du Développement Pharmaceutique des Molécules Biologiques des groupes Serono et Merck Serono, et également Vice-Président Recherche et Directeur R&D Europe d'Ethypharm. Le Dr. Joël Richard a concentré ses activités de recherche sur les nouvelles formulations et les systèmes d'administration de médicaments, tels que les microsphères, les nanoparticules, les polymères, les protéines chimiquement modifiées, la technologie des fluides supercritiques, en particulier pour les préparations injectables de protéines et de peptides. Il a publié 68 articles scientifiques examinés par des pairs, 8 chapitres de livres et il est l'auteur de plus de 130 communications internationales et 53 familles de brevets. Joël Richard est diplômé de l'Ecole Normale Supérieure de Cachan. Il a obtenu son doctorat en science des colloïdes et des interfaces à l'Université Pierre et Marie Curie Paris VI et son Habilitation à Diriger des Recherches en chimie de l'Université Bordeaux I.

inPhocal develops laser-marking machines for industrial production lines. Its optical technology reshapes the laser beam to extend its useful focus range, allowing codes and markings to be applied to curved or irregular surfaces while products move through the line. Applications include expiry dates, traceability information and QR codes on food and beverage packaging, including cans and bottle crowns. The process removes the need for printing ink and is designed to reduce consumables and accommodate changing surface distances. inPhocal integrates its beam technology with machine engineering and controls for high-throughput marking; its published company timeline reports machines installed on customer production lines. INPHOCAL B.V. is based at High Tech Campus Eindhoven and was founded in 2019 from technology identified at CERN through the HighTechXL venture-building program.

Anna van den Boom is published by inPhocal as its CIO, working on the company’s industrial laser-marking technology.

Kathy Vredeveldt is published by inPhocal as its CFO, working on the company’s industrial laser-marking technology.

Martijn Boerkamp is published by inPhocal as its CTO, working on the company’s industrial laser-marking technology.

Robert van Tankeren is published by inPhocal as its CEO and Founder, working on the company’s industrial laser-marking technology.

Sixtine Batais is published by Paris Business Angels as VC Analyst. This is a permanent professional staff function supporting entrepreneur/investor screening, network activity and portfolio follow-up. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Paul Le Coz is published by Paris Business Angels as Chargé d'Investissement. This is a permanent professional staff function supporting entrepreneur/investor screening, network activity and portfolio follow-up. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Yito Etrillard is published by Paris Business Angels as Responsable Communication & Marketing. This is a permanent professional staff function supporting entrepreneur/investor screening, network activity and portfolio follow-up. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Valentin Bernard is published by Paris Business Angels as Directeur Général en charge de la Stratégie et du Développement. This is a permanent professional staff function supporting entrepreneur/investor screening, network activity and portfolio follow-up. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Fabrice Marque is published by Paris Business Angels as Board Member. This is an elected association governance function; its directors also participate in the network’s activities. The directory additionally identifies expertise responsibilities: Lead DEX IA. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Pascal Riviere is published by Paris Business Angels as Board Member. This is an elected association governance function; its directors also participate in the network’s activities. The directory additionally identifies expertise responsibilities: DEX Go-to-Market. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Glenn Grekin is published by Paris Business Angels as Board Member. This is an elected association governance function; its directors also participate in the network’s activities. The directory additionally identifies expertise responsibilities: Recrutements. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Abdelouahab Gasmi is published by Paris Business Angels as Board Member. This is an elected association governance function; its directors also participate in the network’s activities. The directory additionally identifies expertise responsibilities: Co-Lead DEX VC; Comité de Sélection; DEX Sorties / Liquidités. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Jacques-Etienne Grandjean is published by Paris Business Angels as Board Member. This is an elected association governance function; its directors also participate in the network’s activities. The directory additionally identifies expertise responsibilities: Co-Président ESSEC BA; Recrutements ESSEC; Lead DEX Lab' des Référents; DEX Go-to-Market. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Le Prof. Marc-Eric Halatsch est Consultant en Chef de Neurochirurgie à l'Hôpital Cantonal de Winterthour en Suisse. Précédemment, il était Vice-Président du département de Neurochirurgie de l'école de médecine de l'Université d'Ulm en Allemagne; et de 2005 à 2009, professeur associé en neurochirurgie et titulaire de neurochirurgie à l'école de médecine de l'Université de Heidelberg. Ses domaines d'intérêt clinique et de recherche sont la neuro-oncologie et notamment le glioblastome, l'imagenie intra-opératoire, la neurochirurgie pédiatrique, le récepteur de l'EGF et la thérapie ciblée. Il est l'auteur de plus de 70 articles scientifiques dans des publications internationales et participe au comité de lecture de plusieurs journaux scientifiques et médicaux. Le Prof. Marc-Eric Halatsch est dipômé de médecine et docteur en sciences de l'école de médecine de l'Université de Göttingen.

Nancy Faure is published by Paris Business Angels as Board Member. This is an elected association governance function; its directors also participate in the network’s activities. The directory additionally identifies expertise responsibilities: Communication; Comité de Sélection. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Paul Baldwin, pharmacien industriel franco-britannique, est spécialiste de la formulation et du management de projet de R&D. Il dispose de vingt ans d’expérience dans l’industrie pharmaceutique : De 2016 à 2018, le Dr. Paul Balwin a été Pharmacien Responsable Intérimaire de MSD Animal Health Innovation, à Beaucouzé, l’un des trois sites de R&D pharmaceutiques du groupe américain dans le monde. Avant cela, il a occupé au sein du même groupe pendant dix ans le poste de Chef de Projets R&D. Dans ces fonctions, il a eu la responsabilité de diriger des équipes de chercheurs internationales et pluridisciplinaires afin de réaliser le développement pharmaceutique, préclinique et clinique de nouveaux médicaments vétérinaires. Il a ainsi participé ou mené l’enregistrement de quatre nouveaux médicaments, et écrit, révisé ou vérifié plus de dix dossiers d’enregistrement auprès des autorités européennes et américaines. Le Dr. Paul Baldwin a également été galéniste pour Intervet Pharma R&D pendant sept ans, où il a participé à la formulation, au développement et à l’enregistrement de plusieurs médicaments notamment sous forme stériles. Le Dr. Baldwin dispose ainsi d’une très bonne connaissance des systèmes d’assurance qualité (Bonnes Pratiques de Fabrication, de Laboratoires et Cliniques), des textes règlementaires (Pharmacopées européenne et américaine) et des directives pharmaceutiques de l’EMA et de la FDA. Le Dr. Baldwin, inscriptible à l’Ordre National des Pharmaciens, est diplômé de Pharmacie (B.Pharm.) et titulaire d’un doctorat (PhD) en Sciences Pharmaceutiques de l’Université de Nottingham au Royaume-Uni.

GlioCure is an Angers-based French biotechnology company developing investigational medicines for diseases of glial cells, particularly glioblastoma and other difficult-to-treat brain tumours. Founded in September2016 by neuroscience researchers Joël Eyer and Claire Lépinoux-Chambaud with entrepreneur Louis-Marie Bachelot, it originated in research at the University of Angers, Inserm and McGill University. The legal company is GlioCure SA, Angers RCS/SIREN822444840; its April2021 conversion to a société anonyme supersedes old SAS website footer text. Its May2026 announcement confirms continuing development of GC01.1, an injectable formulation of NFL-TBS.40-63 peptide, in final non-regulatory preclinical development for glioblastoma and brain metastases from triple-negative breast cancer. A European formulation patent numbered4593865 was granted with GlioCure as sole owner. These are investigational research and intellectual-property milestones; no clinical efficacy or regulatory approval is asserted. Its wider research portfolio includes GC02 for paediatric brain tumours and GlioVector drug-delivery technology. The public management directory names CEO Louis-Marie Bachelot, Research Director Claire Lépinoux-Chambaud and Pharmaceutical Development Director Paul Baldwin. Four published scientific and medical advisers are external experts. Historical appointments and dated named research staff are qualified separately. Actual financing includes prior equity/quasi-equity, a2020 EUR250K Bpifrance French Tech Seed convertible subscription, an April2021 EUR274500 capital-increase tranche and2021 EUR336K repayable public advances. Cumulative EUR600K seed and nearlyEUR500K bridge totals are not added as extra cash. Patient-association investments through the dedicated GlioCure Capital holding are distinguished from direct donations and from crowdfunding-platform services. Company targets, an unfunded EU Seal of Excellence, and in-kind research awards are not treated as completed cash rounds.

Claire Lépinoux-Chambaud est chercheur en neurosciences. Avant de rejoindre GlioCure, Claire a conduit, au sein de l'Institut de Recherche et d'Ingénierie en Santé (IRIS) de l'Université d'Angers, le programme de maturation engagé par la SATT Ouest Valorisation sur le peptide NFL-TBS.40-63 (GC01). Précédemment à cela, Claire réalisait sa thèse, intitulée « Le peptide NFL-TBS.40-63 issu des neurofilaments : agent thérapeutique et outil de ciblage des cellules de glioblastome et des cellules souches neurales. » au sein du laboratoire de Joël Eyer. Elle est à ce titre auteur principal de plusieurs publications sur le peptide et co-inventeur d'une des trois familles de brevets le protégeant. Dans le cadre de sa recherche doctorale, Claire Lépinoux-Chambaud a pu évaluer la sélectivité d'entrée et les effets de GC01, sur différents types cellulaires et modèles animaux. Elle s'est ainsi spécialisée dans la biologie du cytosquelette neuronal, les cellules souches neurales et le glioblastome ; et a développé une solide maîtrise des techniques de biologie cellulaire et moléculaire, d'imagerie, et d'expérimentation animale. Claire Lépinoux-Chambaud est docteur en neurosciences de l'Université d'Angers et titulaire d'un Master de biologie santé de l'Université de Poitiers.

Louis-Marie Bachelot est bio-entrepreneur en santé humaine. Il dispose de près de vingt ans d'expérience dans le secteur des biotechnologies appliquées à la santé humaine. Louis-Marie Bachelot a notamment initié en 2007 une activité de management de projet de développement thérapeutique au sein du cabinet de conseil spécialisé en innovation ALCIMED. Dans ce cadre, il a accompagné avec son équipe trois programmes précliniques et cliniques de thérapies innovantes sur des maladies rares dont deux sur le système nerveux central et conduit les travaux réglementaires permettant l'obtention de deux désignations de médicaments orphelins. A partir de 2009, Il a poursuivi le management de l'un d'eux de manière indépendante et porté les premières étapes de transfert de ce programme vers un projet de création d'entreprise pour lequel il a été lauréat du concours national d'aide à la création d'entreprise de technologies innovantes dans la catégorie Emergence en 2011. Louis-Marie Bachelot a également co-fondé en 2007 la société SISENE dont il a été le responsable financier jusqu'en mars 2014. SISENE développait, avec le soutien des Laboratoires THEA, des thérapies innovantes anti-angiogéniques en oncologie et ophtalmologie. Louis-Marie Bachelot est diplômé de Sciences-Po Paris, section économique et financière, il est titulaire d'un Master of Sciences en biochimie et biologie moléculaire du King's College de Londres, et d'une licence d'histoire de l'Université Catholique de l'Ouest à Angers.

Nathalie Dubiez is published by Paris Business Angels as Board Member. This is an elected association governance function; its directors also participate in the network’s activities. The directory additionally identifies expertise responsibilities: DEX Lab' des Référents; DEX Exits. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Sophie Dutilloy is published by Paris Business Angels as Board Member. This is an elected association governance function; its directors also participate in the network’s activities. The directory additionally identifies expertise responsibilities: DEX Go-to-Market; DEX Onboarding & Accompagnement des membres; Comité de Sélection. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Stéphanie Barreau is published by Paris Business Angels as Board Member. This is an elected association governance function; its directors also participate in the network’s activities. The directory additionally identifies expertise responsibilities: Co-Lead DEX VC; Comité de Pré-sélection. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Henri Assaf is published by Paris Business Angels as Board Member. This is an elected association governance function; its directors also participate in the network’s activities. The directory additionally identifies expertise responsibilities: Lead DEX Onboarding & Accompagnement des membres; DEX IA. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Jean-Louis Rouze is published by Paris Business Angels as Secrétaire Général & Trésorier. This is an elected association governance function; its directors also participate in the network’s activities. The directory additionally identifies expertise responsibilities: Lead DEX SPV. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Jean-Marc Tenenbaum is published by Paris Business Angels as Vice-Président. This is an elected association governance function; its directors also participate in the network’s activities. The directory additionally identifies expertise responsibilities: Lead DEX* Exits. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Olivier Baroux is published by Paris Business Angels as Président. This is an elected association governance function; its directors also participate in the network’s activities. The network role does not establish a personal investment or employment at portfolio companies. Earlier career or appointment dates are not publicly established by this directory.

Paris Business Angels is a French nonprofit angel-investor network constituted as a law1901 association, RNA W751160767 and SIREN450983812. It connects entrepreneurs with member investors, screens early-stage opportunities and coordinates expert-led diligence, investment structuring and portfolio support. The current published team comprises thirteen elected governance members and four permanent staff, led by president Olivier Baroux. An older legal page names predecessor Elisabeth Lecuyer; this is historical rather than current leadership. Member investments are usually coordinated through deal-specific SPVs (the network publishes approximately80percent), not automatically paid from association treasury. A source naming the network therefore establishes a collective platform relationship without proving a particular member or subscribing SPV. Published cumulative deployment and average tickets are not LP fund closes or exact company allocations. Its portfolio includes AI, deep technology, biotechnology and neurotechnology. No current public LP fundraising close is established.

Sam Kothari is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Startup Advisor; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Tanya Raheja is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as General Manager at Canva; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Akanksha Mehta is published in Transformation Capital’s Investment team. Published education: Wellesley College, BA in Economics and Philosophy. Published career background: Fisher Lynch Capital; Deutsche Bank. These background listings do not establish current external appointments.

Akhi Samant is published in Transformation Capital’s Investment team. Published education: NYU Stern School of Business, BS in Finance and Economics. Published career background: Goldman Sachs. These background listings do not establish current external appointments.

Amy Slizofski is published in Transformation Capital’s Operations team. Published education: Tulane University, BA in Sociology. Published career background: SV Health Investors; BV Investment Partners; Baupost Group. These background listings do not establish current external appointments.

Ashley Kurpinsky is published in Transformation Capital’s Operations team. Published education: University of Colorado, BS in Psychology. Published career background: Generation Investment Management; Golden Gate Capital; Alliance Partners (BancAlliance); Saints Capital. These background listings do not establish current external appointments.

Bhooshi de Silva is published in Transformation Capital’s Partner Acceleration team. The manager biography identifies him as a Thermo Fisher strategic-capital leader and PPD corporate development/strategy/ventures executive; the Partner Acceleration directory is a published affiliation, not proof of employment by Transformation Capital.

Brendan Kish is published in Transformation Capital’s Investment team. Published education: Pomona College, BA in Mathematics and Economics. Published career background: TD Cowen. These background listings do not establish current external appointments.

Briana Blake is published in Transformation Capital’s Operations team. Published education: Plymouth State University, BS in Marketing. Published career background: MIT Sloan School of Management. These background listings do not establish current external appointments.

Christine Murphy is published in Transformation Capital’s Operations team. Published education: Bryant University, BS; SUNY Albany, MS in Taxation. Published career background: PwC. These background listings do not establish current external appointments.

Hannah Ahn is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Founder at Flair; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Jenna Ciotti is published in Transformation Capital’s Investment team. Published education: Yale University, BS in Psychology with Distinction; Yale School of Public Health, Master of Public Health (MPH). Published career background: M33 Growth; The Ripples Group. These background listings do not establish current external appointments.

Jessica Pellegrini is Head of Capital Formation at Transformation Capital. Published education: Harvard College, BA. Published career background: Spark Capital, Third Point, Engle Capital, Barclays, Lehman Brothers. These background listings do not establish current external appointments.

Julie Murchinson is published in Transformation Capital’s Partner Acceleration team. Published education: Franklin and Marshall College, BA in Business Management & Accounting; The Wharton School at the University of Pennsylvania, MBA in Healthcare and Operations Management. Published career background: Board Director of National Committee for Quality Assurance and Advisor to University of Pennsylvania’s Leonard Davis Institute of Health Economics and Scottsdale Institute; Health Evolution; Manatt Health; CareScience; Deloitte; Ernst & Young. These background listings do not establish current external appointments.

Karen Saldana is published in Transformation Capital’s Operations team. Published education: Mount Ida College, BS. Published career background: Artisan Partners. These background listings do not establish current external appointments.

Kevin Brown is published in Transformation Capital’s Operations team. Published education: Suffolk University, MBA in Finance; Stonehill College, BS in Accounting; CPA. Published career background: PEVC Financial Services; SVB Leerink; Charlesbank Capital Partners; Harvard Private Capital at Harvard Management Company; Former Suffolk University Accounting Advisory Board. These background listings do not establish current external appointments. Distinct from the Standard Model Biomedicine CEO named Kevin Brown.

Laurel Smith is Director of Investor Relations at Transformation Capital. Published education: University of Massachusetts, Boston, BS. Published career background: Leerink Partners; Advent International; Stonegate Group; City of Framingham, MA. These background listings do not establish current external appointments.

Layla Behrouzian is published in Transformation Capital’s Investment team. Published education: BA in Economics at UC Berkeley. MBA at Harvard Business School.. Published career background: Goldman Sachs, CareRev. These background listings do not establish current external appointments.

Mike Dixon is Managing Partner at Transformation Capital. Published education: Boston College, BS and member of the Presidential Scholars Program. Published career background: Sequoia Capital; Fidelity Management & Research Company. These background listings do not establish current external appointments. Distinct from Sanderling’s Michael Dixon, the Canadian accounting/Therillia executive; this manager biography instead identifies Sequoia/Fidelity and Boston College background.

Nick Briguglio is published in Transformation Capital’s Investment team. Published education: Boston College Carroll School of Management, BS in Finance and Entrepreneurship. Published career background: Deutsche Bank. These background listings do not establish current external appointments.

Nicole Bleecker is published in Transformation Capital’s Partner Acceleration team. Published education: Emory University, BS in Neuroscience & Behavioral Biology, The Wharton School at the University of Pennsylvania, MBA in Healthcare Management. Published career background: Ambience Healthcare, Outpatient Imaging Affiliates, Hims & Hers, EY, Navigant Consulting (Guidehouse). These background listings do not establish current external appointments.

Raphael Cervantez is published in Transformation Capital’s Investment team. Published education: Columbia University, BA in Neuroscience. Published career background: Goldman Sachs. These background listings do not establish current external appointments.

Robin Borg is published in Transformation Capital’s Partner Acceleration team. Published education: University of Minnesota, BA in Communications; Masters courses in Organization Leadership; SPHR Certification from the Society for Human Resource Management. Published career background: DexCare; Galileo; Bind; PeopleServe; Optum; Boston Scientific; Abbott. These background listings do not establish current external appointments.

Robin Mercer is published in Transformation Capital’s Partner Acceleration team.

Scott Rosen is published in Transformation Capital’s Investment team. Published education: University of Virginia, BS in Commerce with a double major in Economics, Sky Alland Scholarship. Published career background: Cigna/Express Scripts/eviCore; Court Square Capital; Evercore. These background listings do not establish current external appointments.

Tanya Wesley is published in Transformation Capital’s Partner Acceleration team. Published education: University of Irvine, BA in Literary Journalism; California State University Long Beach, MA in Women’s History. Published career background: TSG Consumer Partners; Power Presentations. These background listings do not establish current external appointments.

Todd Cozzens is Managing Partner at Transformation Capital. Published education: Marquette University; Harvard Business School, PMD. Published career background: Sequoia Capital; Picis (UHG); Marquette Medical Systems (GE). These background listings do not establish current external appointments.

Vinay Shah is published in Transformation Capital’s Investment team. Published education: Princeton University, BA focused on health policy; The Wharton School of the University of Pennsylvania, MBA in healthcare management. Published career background: Longitude Capital; Bain & Company; Sherpa Clinical. These background listings do not establish current external appointments.

Wayne Reuben is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Founder at engage4performance; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Sam Sterling is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Managing Director, Strategy at AKQA; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Remy Wheat is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Strategy Lead at Canva; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Pablo Gil Brusola is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Co-Founder at PropHero; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Mark Finn is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Co-Founder & CFO at ROLLER; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Edouard Lyndt is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Product Manager at Airwallex; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

David Wei is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Startup Advisor; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Duncan Allan is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Senior Growth Manager at Google; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Dane Hudson is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Founder & CEO at Impactful Leadership Consulting; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Collin Li is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Resident at AfterWork Ventures; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Cecelia Chang is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Deputy CEO at Mission Barns; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Carson Au is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Technical Lead at Arista Networks; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Abhishek Maran is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Investor at Rampersand; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Matt Joass is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as CIO at Maven Funds; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Tim Rossanis is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Managing Director at Turo Australia; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Alex Downie is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Associate Director at Glow Capital Partners; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Fab Mackojc is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Entrepreneur In Residence at AfterWork Ventures; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Anna Cheng is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Growth Lead at HealthMatch; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Daniel Tram is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Head of Product at Edrolo; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Olivia Grivas is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Investor at Skip Capital; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Nan Meka is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as VP Commercial and Planning at Pet Circle; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Max Marchione is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Founder at Stealth Company; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Anna Podolsky is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Founder and CEO at Lyka; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Startup operator with experience supporting Pixis expansion and working with early founders at Entrepreneur First. Published only in pi Ventures team structured data; current membership is unverified.

Entrepreneur and venture investor who previously co-founded an education-technology startup and led its AI and business activities.

Entrepreneur and investor who co-founded solar company Aeon Solaris and previously led commercial activities at carbon-removal company Skytree.

Management consultant turned product leader who worked at NephroPlus and Loadshare. pi Ventures publishes him in team structured data; current membership is unverified.

Chartered accountant with private-equity and fund-administration experience, responsible for legal, finance, compliance and investor relations at pi Ventures.

Glen Riddell is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Co-founder and COO at Plenti; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Michael Malek is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Software Engineer at Tesla; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Alexander Jutkowitz is a published external adviser/operational partner of Seaside Ventures. The own manager identifies the expertise/capacity as Founder & Growth Investor. The directory does not give a detailed career biography or appointment date; this is an external advisory affiliation, not a claim of employment as a venture investment partner. Source scope: current own published named capacity; no inferred pastemployer, startdate or personal cashcheck.

Matthew Tracey is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Strategy at Palantir; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Benjamin Buckingham is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Chief Product Officer at Identiti; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Kevin Sprouse is a published external adviser/operational partner of Seaside Ventures. The own manager identifies the expertise/capacity as Sports Physician. The directory does not give a detailed career biography or appointment date; this is an external advisory affiliation, not a claim of employment as a venture investment partner. Source scope: current own published named capacity; no inferred pastemployer, startdate or personal cashcheck.

Matthew Jung is a published external adviser/operational partner of Seaside Ventures. The own manager identifies the expertise/capacity as Founder & CEO. The directory does not give a detailed career biography or appointment date; this is an external advisory affiliation, not a claim of employment as a venture investment partner. Source scope: current own published named capacity; no inferred pastemployer, startdate or personal cashcheck.

Timothy Mohn is a published external adviser/operational partner of Seaside Ventures. The own manager identifies the expertise/capacity as CTO & Advisor. The directory does not give a detailed career biography or appointment date; this is an external advisory affiliation, not a claim of employment as a venture investment partner. Authentic portrait unavailable: own cartoon avatar rejected. Source scope: current own published named capacity; no inferred pastemployer, startdate or personal cashcheck.

Zezan Tam is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Angel Investor; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Ben Van de Bunt is a published external adviser/operational partner of Seaside Ventures. The own manager identifies the expertise/capacity as Founder & CEO. The directory does not give a detailed career biography or appointment date; this is an external advisory affiliation, not a claim of employment as a venture investment partner. Source scope: current own published named capacity; no inferred pastemployer, startdate or personal cashcheck.

Daniel Wirjoprawiro is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as CTO at Certane; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Lucy Wark is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Founder at Normal; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Nicola Munarini is a published external adviser/operational partner of Seaside Ventures. The own manager identifies the expertise/capacity as VC partner. The directory does not give a detailed career biography or appointment date; this is an external advisory affiliation, not a claim of employment as a venture investment partner. Source scope: current own published named capacity; no inferred pastemployer, startdate or personal cashcheck.

Jethro Cohen is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Venture Capital Investor at Square Peg; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Ryan Greene is a published external adviser/operational partner of Seaside Ventures. The own manager identifies the expertise/capacity as Medical Director. The directory does not give a detailed career biography or appointment date; this is an external advisory affiliation, not a claim of employment as a venture investment partner. Source scope: current own published named capacity; no inferred pastemployer, startdate or personal cashcheck.

Ben Greenfield is a published external adviser/operational partner of Seaside Ventures. The own manager identifies the expertise/capacity as Biohacker & Human Performance Expert. The directory does not give a detailed career biography or appointment date; this is an external advisory affiliation, not a claim of employment as a venture investment partner. Source scope: current own published named capacity; no inferred pastemployer, startdate or personal cashcheck.

Ben Milsom is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Co-Founder at Plenti; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Harrison Valner is Managing Partner of Seaside Ventures. At Seaside, Harry leads external engagement, focusing on building and maintaining key relationships with founders, operational partners, and investors. His active involvement in industry events and partnerships ensures that Seaside remains connected to top-tier deal flow and emerging opportunities. With expertise in operations, logistics, and product development, Harry supports portfolio companies in optimizing manufacturing, distribution, and scaling strategies. His experience in developing and launching consumer health products helps founders transition from concept to commercialization effectively. Additionally, Harry’s focus on network expansion connects startups with industry-leading resources and partnerships that drive sustainable growth. Source scope: current own published named capacity; no inferred pastemployer, startdate or personal cashcheck.

Ivan Lim is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as CEO at BROSA; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Niamh Mooney is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as Founder at Software; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Ryan Roddy is Managing Partner of Seaside Ventures. At Seaside, Ryan leads internal strategy with a focus on due diligence, investment strategy, and market analysis. His methodical approach ensures Seaside’s investments are strategically aligned for long-term success and contribute to impactful health solutions. With a sector focus on longevity, brain health and cognition, and human performance, Ryan targets innovations that improve health outcomes and quality of life. Drawing on his expertise in investment strategy, marketing, and brand building, Ryan supports portfolio companies in achieving product-market fit, competitive positioning, and scalable market growth. Source scope: current own published named capacity; no inferred pastemployer, startdate or personal cashcheck.

Cheryl Mack is publicly named in AfterWork Ventures’ operator community. The undated manager directory describes outside experience as CEO at Aussie Angels; this is source-published context, rather than independently verified current employment. The affiliation supports the manager’s community approach to sourcing, investment assessment and portfolio support and does not establish a personal LP ticket or company investment.

Derek Callow is Operating Partner of Seaside Ventures. At Seaside, Derek leverages his deep expertise in marketing and consumer engagement to guide portfolio companies in building brand awareness and competing in dynamic markets. His executive leadership experience enables him to offer hands-on support, advising on product-market fit, operational strategies, and international growth. Additionally, Derek’s extensive network and strategic insights create opportunities for market access and partnerships, helping Seaside’s investments achieve meaningful and sustainable growth. Source scope: current own published named capacity; no inferred pastemployer, startdate or personal cashcheck.

Seaside Ventures is the US early-stage health and wellness venture manager operating seasideventures.com, distinct from protected Seaside Equity Partners Investor4613 and from unrelated therapeutics companies. Exact regulatory/filing identity is Seaside Ventures Management, LLC, CRD317945. Its March31,2025 primary SEC FormADV identifies that legal adviser; the exact FormD of Delaware Seaside Ventures FundI LP (CIK1904117, organised2021) identifies the management company, Seaside Ventures FundI GP LLC and Harrison Valner as manager of the fund general partner. Adviser identity is not an inference that the platform is a different registered bank, fund or manager. No unsupported exact manager founding date or current SEC-registration status is asserted. Seaside focuses on science-driven consumer health, commercialisation and preventive personalised care. Own public thesis covers brain health and cognition, physical and mental wellbeing, and translating validated innovations into accessible products. Own contact FAQ says idea-stage through seed, typicallyUSD250K, with UnitedStates/Canada/Europe geography; the broader about page lists incubation, preseed, seed and SeriesA. These strategy ranges are not individual disclosed tickets. Its Seaside Syndicate provides accredited participants with deal-specific SPVs alongside FundI or laterstage opportunities. Syndicate minimums, average-size marketing and deployment targets are not actual closed LP funds or fresh issuer cash; no duplicate fund/manager/personal check is inferred. The published core team is managing partners Harrison Valner and Ryan Roddy and operating partner Derek Callow, all with genuine individually named own portraits and substantive biographies. Own external-adviser directory lists nine humans separately from investment staff: Matt Johnson, Ben Greenfield, Ryan Greene, Nicola Munarini, Ben Van de Bunt, Matthew Jung, Kevin Sprouse, Timothy Mohn and Alexander Jutkowitz. Their titles denote external expertise, not Seaside employment or personal investment subscriptions. The dog Diego is a mascot, not a Person. The existing ThisLife cofounder MattJohnson has a possible connection to the own Seaside adviser who links to TheFeed’s MattJ professional profile, but a sufficient primary career/identity bridge was not established. That protected Person remains unchanged; the uncertain adviser identity is documented rather than silently merged or duplicated. Eight other human adviser affiliations are imported with own published capacities; seven have authentic portraits and Timothy Mohn’s cartoon avatar is rejected; detailed independent career biographies are not published in the manager directory. Unknownappointment dates remainNULL. The own SF/NY office section retains obvious InvestorX template addresses, investorx.com contact emails and named template stock photos. These are rejected as actual manager offices. The historical2022 SECaddress in Boulder is qualified with its filingdate; no present headquarters is inferred from a template. The logo is original individually captioned official SeasideVenturesLogo, and uploaded team images are authentic own-source photographs, visually checked, with no fabricated faces. FundI’s April25,2022 original FormD records indefinite offering and zero sold beforefirstsale. A later managing-partner own announcement says firstclose completed and initialcapitalcalled, while explicitlycallingUSD10M a target, not a proved finalclose. Accordingly exactclosedsize and announcementday remainNULL. FundI is a distinct verified legalpartnership, not a secondmanager. SubsequentSPVs/currentadditionallegalfunds, GAV/AUM and exactfullfinalclose are unproven and not invented. Own portfolio confirms neural sleep headband Somnee, menstrual-neurotechnology Samphire Neuroscience, AIneurological-drug-discovery PangeaBio, reinforcement-learning ICU dosing Strive, AI-enabled microbiome infrastructure BiomeSense and aptamer biosensor Adaptyx alongside other health/biotech/materials businesses. Twenty-three own portfolio cards are queued for fullissuer identity/clinical/funding audits. Portfolio product/approval assertions are source-published marketing, not independently verified regulatory or clinical outcomes. The Samphire portfolio’s Preseed2023 card and uniformly2025 investor-page dates are classification/content fields, not financing dates. Actualtransaction counsel names Seaside among participants in Samphire’s USD2.3Mpreseed publiclyannouncedFebruary2024; issuer owner retainsone source-qualifiedactualparticipation with ticketNULL, noUSD250Kdefault or personalHarry/Ryancheck. The Fortify managing partner’s own announcement independently names Seaside as an existing-investor participant in Samphire’s actual USD5M2025 seed financing (retained issuer event publiclyannouncedJune5,2025). This is distinct from the actual2024preseed and is not inferred from the portfolio’s inconsistent calendar fields. The company-profile owner adds exactlyoneundisclosed-ticket nonlead follow-on; exactsubscriptionvehicle and fund/person allocation remainunpublished.

Adam Smith is AfterWork Ventures’ published venture partner, identified by its own named portrait and adamrsmith2 professional-profile link. He co-authored the manager’s Samphire Neuroscience investment note, which explicitly confirms its pre-seed backing. He is distinct from the UK real-estate Investment and Leasing Director Adam Smith already present in Adex.

Mike Forster is AfterWork Ventures’ published venture partner and an author of investment notes. Its2021OfferFit note identifies his contemporary outside work as Director of Data and Analytics at KFC Global, informing assessment of enterprise-marketing AI. That dated outside position is not asserted as current2026employment.

Bella Acton, also published as Annabel Acton and linked by the manager to the same annabelacton professional profile, is AfterWork Ventures’ creative director. She writes its founder-support, brand and consumer-business investment analyses. The public aliases describe one person rather than separate core and community employees.

Adrian Petersen is a published AfterWork Ventures partner and contributor to its investment and founder-support writing. In his own2021account he described founding and leading veri.vote, a blockchain-based electronic-voting startup in2016, before its closure. He supports the manager’s pre-seed and seed investment work.

Alex Khor is published as a partner at AfterWork Ventures. The manager’s OfferFit investment note describes his previous consulting work at QuantumBlack, McKinsey’s advanced analytics arm, and his experience assessing enterprise applications of machine learning. His venture work includes the manager’s early-stage AI and neurotechnology investments.

AfterWork Ventures is an Australian community-powered venture capital manager investing at pre-seed and seed stages, with an Australia and New Zealand focus and some global investments. The exact operating entity is AfterWork Ventures Pty Ltd, ACN 650085251 and ABN 36650085251, active in the Australian Business Register from 8 July 2021. Its own regulatory footer identifies corporate authorised representative 1288519 of Boutique Capital Pty Ltd, ACN 621697621, under AFSL 508011; that licensing relationship does not make Boutique Capital a subscribing buyer in AfterWork portfolio companies. The manager launched professionally in March 2021, following a community micro-fund raised in November 2019; legal registration, professional launch and earlier angel activity are distinguished. Its published core team is partners Alex Khor and Adrian Petersen, creative director Bella Acton (also publicly Annabel Acton), and venture partners Adam Smith and Mike Forster. The site separately publishes an operator community supporting sourcing, due diligence and portfolio companies. Community membership is not automatic operating employment, membership does not prove a personal investment, and undated outside-company titles are retained as historical/source-published context. Former partner Jessy Wu publicly described leaving in July 2024; older 2021–2022 team material is not used to make her a current partner. The published count of over 100 or 120 operators is not turned into a private unnamed staff list. Own primary sources identify historical Fund I and Fund II and the professional AfterWork Fund III. Fund III announced an actual first close on 16 August 2021 after reaching AUD 10 million in commitments. AUD 30 million was the fundraising target; the first close is not a final AUD 30 million cash close. The investor page’s AUD 20 million funds under management and 54 investments is an undated historical snapshot accompanied by an August 2022 application deadline, not evidence of a new fund close or current 2026 AUM. Fund I/II amounts, legal subscribing vehicle names and closing days remain unpublished in the reviewed primary sources. Its own investment note explicitly identifies AfterWork as a pre-seed investor in Samphire Neuroscience alongside HAX; the note was published 25 January 2022, without proving that date as cash closing or an individual ticket. This establishes relevance to women’s-health neurotechnology. The portfolio and investment notes also include AI companies such as OfferFit, PropHero, SwingVision and Avarni. The 2021 OfferFit note distinguishes AfterWork’s May 2021 pre-Series A investment from the later Canvas-led USD 14 million Series A; the manager later announced its exit following acquisition by Braze. Portfolio affiliation is not asserted to be a current unexited holding. Neuroscience product claims are company/manager descriptions rather than unconditional medical-efficacy or approval assertions. Actual issuer participations are imported only against source-proven records, and missing issuers are queued for complete profiles rather than bare placeholders.

Eric Brook was a partner at Ayuh Ventures in its founder-authored2022annualreport. Current B Capital biography identifies his Ayuh and Prithvi investment roles as previous positions, where he led diligence and supported climate and healthcare portfolio companies. He is now an associate on B Capital’s energy investment team in San Francisco, focused on growth-stage energy infrastructure and industrial resilience. Earlier work included business development at a San Francisco family office. He holds a BA in philosophy and political science from Tufts University. Exact end date of the Ayuh role is not established by the primary sources. Current primary B Capital biography reviewed October8,2026: Eric Brook is an Associate on the Energy investment team at B Capital, where he focuses on growth-stage investments in energy infrastructure and industrial resilience. Prior to B Capital, Eric held investment roles at Ayuh Ventures and Prithvi Ventures, leading diligence and supporting portfolio companies across climate tech and healthcare. He also worked at an SF-based family office, where he led business development for emerging growth initiatives. Eric holds a B.A. in Philosophy and Political Science from Tufts University and is based in San Francisco.

Vivek Soni is named as a member of Ayuh Ventures in its2022annualreport; a current Ayuh appointment has not been independently established. Primary2025issuer biography describes his operating-partner work at Prithvi Ventures and management of Boston Cleantech, supporting businesses in energy, chemicals, materials and manufacturing. His historical roles include Nomura cleantech advisory work and leadership at TiE Boston Angels. He holds BTech education at IIT NewDelhi and MS/PhD qualifications in polymer science and engineering at the University of Massachusetts Amherst. These career roles are source-dated and do not imply personal cash participation.

Kunal Sethi is a general partner and founder of Ayuh Ventures, investing in neuroscience, longevity and patient-focused healthcare. His publicly authored reports describe establishing the firm in2021 and expanding its investment focus beyond psychedelics. He also leads Prithvi Ventures, a distinct climate and energy investment brand. Its current biography describes more than20years in cleantech and degrees in economics and environmental sciences from Charles Sturt University and the University of Mumbai. Native SEC records identify him as manager of an Ayuh Delaware series; a manager signature is not a personal investment.

Murali Sethumadhavan is an operating partner at Ayuh Ventures, according to the current primary team biography published by Prithvi Ventures. He is a materials scientist with more than30years in R&D and innovation and over35patents. His career includes commercializing polymer-science products at Rogers Corporation and Bose Corporation. He holds a PhD in polymer science from the University of Massachusetts Amherst and an MTech from the Indian Institute of Technology. His expertise connects materials and healthcare. Outside board memberships and angel activity do not establish a personal check in any Ayuh portfolio company.

Parkins Burger is an attorney and legal contributor to Ayuh Ventures. The firm’s2022report labels his function Legal, and its current AngelList syndicate lists him on the team without a partner designation. His law-practice biography describes corporate governance, corporate and financial transactions, business formation, cross-border mergers and joint ventures, and US investor immigration. He holds a BA from Oberlin College and a JD from Temple University and has practiced as an American attorney since2005. Legal and syndicate affiliations are distinct from a general-partner investment appointment.

Ayuh Ventures is an early-stage US healthcare investment firm founded in2021, focused on neuroscience, mental health, psychedelics, aging and fertility. Its own site identifies Ayuh Ventures LLC, and native SEC records identify a Delaware series fund with Kunal Sethi as manager. Its AngelList syndicate is supervised by or affiliated with Prithvi Ventures LLC; the two brands have different mandates and remain distinct. The current publicly documented team includes general partner Kunal Sethi, operating partner Murali Sethumadhavan and syndicate legal contributor Parkins Burger. Its2022report also names Eric Brook and Vivek Soni; those historical affiliations are qualified rather than asserted as current. The2021legal series reported USD713000 fully sold, but later branded longevity FundI and FundII final sizes and closes remain unverified. Its investments include neurotechnology, drug discovery and mental-health care; investment theses and portfolio clinical claims are not evidence of established treatment efficacy.

QT Sense develops Quantum Nuova, a benchtop quantum-sensing microscope for studying free-radical activity in living cells and tissues. The platform uses fluorescent nanodiamonds containing nitrogen-vacancy centers, confocal optics and T1 relaxometry to measure local magnetic noise associated with oxidative stress. Its Quantum Pulse software controls acquisition, sensor relocation and analysis so researchers can observe cellular responses to drugs over time. The company serves academic and pharmaceutical research, including drug discovery, oncology, infectious disease and neurodegeneration. Its neurological research applications investigate oxidative stress in neurons and glia and potential responses to neuroprotective drugs in conditions such as Alzheimer’s disease, Parkinson’s disease and ALS. These are research applications and development aims; the cited sources do not establish regulatory clearance for diagnosing patients. QT Sense B.V. was founded in 2024 as a spin-out from the University Medical Center Groningen.

Deepak Veeregowda is published by QT Sense as its CEO and Co-founder.

Elkin Escobar is published by QT Sense as its Application Scientist.

Hoang Nguyen is published by QT Sense as its COO and Co-founder.

Romana Schirhagl is published by QT Sense as its CSO and Co-founder.

Seyyed Taheri is published by QT Sense as its CTO.

Lightcone Ventures founding partner with a background in fund formation and investor relationships. Previously chief of staff at Prime Movers Lab.

Works in investor relations at Lightcone Ventures. His published background spans capital formation, venture investing and strategic partnerships.

Lightcone Ventures provides growth capital to deep-tech companies building physical infrastructure and industrial technologies. Its investment strategy covers energy generation and storage, critical resources, satellites and orbital infrastructure, advanced manufacturing, industrial automation, robotics and embodied AI, advanced computing and defense technologies. Within these areas it targets technologies such as nuclear energy, semiconductor and photonics infrastructure, autonomous systems and industrial AI. The published leadership combines founder and operating experience with investment and capital-formation backgrounds. SEC adviser records identify the business as Lightcone Venture Capital, LLC, operating as Lightcone Ventures; the legal manager is separately identified as manager of Lightcone Venture Capital I LP. A September 2026 offering notice establishes that fund vehicle but does not establish a first or final fundraising close.

Reyedar develops SONDA, an eye-tracking platform that measures visual function while a patient follows a moving target. Wearable infrared sensors record gaze and eye movement, and its software analyzes the signals to produce a clinical visual-function report without button presses. The system combines eye-movement perimetry and oculomotor assessment for use in optometry practices and ophthalmology clinics. Reyedar identifies SONDA software as a CE-marked Class IIa medical device under the EU Medical Device Regulation, intended to detect visual function loss as an aid in diagnosing and staging primary open-angle glaucoma in adults; the hub is Class I hardware. Its functional oculomics research investigates eye-movement biomarkers in conditions such as spinocerebellar ataxia and acquired brain injury. Those applications remain research and are outside SONDA’s cleared clinical use. Reyedar B.V., formerly Reperio Medtech, is a spin-off of the University Medical Center Groningen.

Founder of Reyedar, identified as its CEO in primary investor announcements in 2023. His work applies eye tracking and computational neuroscience to visual-function assessment; older sources use Alessandro Grillini.

Co-founder of Reyedar, identified as its Chief Commercial Officer in NOM’s November 2023 interview on commercializing SONDA visual-function assessment. Current appointment is unverified.

Frédéric Saudou is HuntX Pharma’s chief scientific officer and cofounder. His published biography identifies him as a professor at the Grenoble Institute of Neuroscience since 2013 and a former institute director from 2013 to 2023. His research studies huntingtin, axonal transport and neuronal dysfunction. He trained in molecular pharmacology and human genetics at Strasbourg with R. Hen and J. L. Mandel, completed a Harvard Medical School postdoctorate with M. E. Greenberg, and returned to France as an Institut Curie group leader in 2000. The company identifies a 2014 Richard Lounsbery Prize and more than 100 research publications. His current HuntX title is distinguished from his historical institute directorship.

Laure Jamot is HuntX Pharma’s president and cofounder. Her published biography describes a neuroscientist with 20 years of preclinical and clinical development experience, including seven years on Huntington’s disease, and an inventor on granted patent families. She previously cofounded The Healthy Aging Company (THAC), where she served as CSO/COO. Her career includes rare-disease clinical development, scientific training at Université René Descartes, HEC Challenge+ business education, and academic work at Mount Sinai in Toronto and Pitié-Salpêtrière in Paris. These company-published career statements do not imply current affiliations with prior institutions.

HuntX Pharma is a French neuroscience biotechnology company founded in December 2022 by Laure Jamot and Frédéric Saudou. It develops small-molecule therapies for neurological diseases involving impaired axonal transport. Its first candidate, HX127, targets Huntington’s disease and aims to restore transport of brain-derived neurotrophic factor between neuronal regions. The company uses microfluidic brain-on-a-chip models and imaging to identify compounds; an AI platform is not inferred. Published efficacy statements concern developer-reported preclinical models, rather than established clinical benefit or an approved treatment. Its 2024 release planned regulatory animal studies and a future 2026 Phase 1 trial; current completion is unverified. The website’s legal owner is SAS HuntX Pharma, SIREN 921853990, with research contacts in Grenoble/La Tronche. It announced EUR 1.7M raised on September 19, 2024 from Angels Santé, Paris Business Angels, Grenoble Angels and unnamed patient families. These network attributions represent members or syndicates, not proof of association treasury allocations. SATT Linksium is separately named as an incubator and existing shareholder. Bpifrance/France 2030 support and Ipsen’s 2024 Golden Ticket are qualified separately from priced equity financing.

Sanos Capital is a New York-based venture investment platform focused on digital health. Reveal HealthTech’s issuer release describes it as an operator-led venture capital fund that works with founders to scale technologies for care delivery, patient experience and healthcare-system improvement. Its publicly confirmed investments include Reveal HealthTech’s September2025 Series A and a co-led seed investment in Everbright Health, a technology and managed-services business supporting interventional psychiatry within existing mental-health practices. These investments connect the platform to healthcare AI, care-delivery infrastructure and mental health.

Circular Genomics develops blood-based circular RNA biomarkers and analytical tools for research into neurological and psychiatric disorders. Its CircPath platform profiles brain-derived circRNAs to investigate disease pathways, identify biomarkers and characterize patient cohorts. Published applications include Discover 1600+ for broad circRNA profiling, AD Detect for research into biomarker-defined Alzheimer’s disease biology, and AD Predict for research into future cognitive impairment and symptom progression. The current CircPath applications are labelled for research use only and are not intended for diagnostic procedures. The company also announced the historical launch of MindLight in September 2024, a blood assay intended to help clinicians assess antidepressant response in major depressive disorder; its present availability is unverified. Circular Genomics works with academic and biopharma partners on biomarker validation and licensed intellectual property, with headquarters at Lilly Gateway Labs in San Diego.

Circular Genomics cofounder whose historical role as president and director is documented in its 2021 issuer announcement and regulatory filing. Current operating responsibilities are unverified.

Commercial advisory board member of Circular Genomics. The company identifies him as CEO of Poplar Grove Investors and describes his pharmaceutical commercialization experience at Abbott and Eli Lilly, healthcare investment-banking background and Harvard MBA.

Neurogenomics researcher listed on Circular Genomics’ scientific advisory board. The company identifies his psychiatry and neurology professorship at Washington University School of Medicine and his research on brain-derived circular RNA biomarkers.

Diagnostics commercial executive whose appointment as Circular Genomics chief commercial officer was announced in February 2024. The current executive directory names a different chief commercial officer; his present company affiliation is unverified.

Scientific advisory board member of Circular Genomics. Its directory identifies her work in translational psychopharmacology at the Centre National de la Recherche Scientifique.

Chief financial officer listed on Circular Genomics’ current executive team. Additional career history is not supplied in its public directory.

Value-based care and health-system analytics executive serving on Circular Genomics’ commercial advisory board. His own company biography names him James Grana and describes his BlueCross BlueShield of South Carolina role and previous payer, provider and analytics positions.

Cofounder and managing director of Mountain Group Partners and a Circular Genomics board member. Previously worked in private placements and investment banking; studied economics at Davidson College. Regulatory filings identify the same director as Joseph Cook III.

Circular Genomics cofounder identified as advising CIO in company-authored November 2024 content. Current advisory appointment is unverified.

Circular Genomics commercial adviser with expertise in pharmaceutical pricing, payer engagement and patient-support programs. Founder of Endeavor Pharma Solutions and former Lilly commercial leader; holds a Harvard MBA.

Commercial adviser to Circular Genomics with experience in reimbursement, commercialization and healthcare strategy. Her biography describes former Evernorth leadership and prior work at UnitedHealth, Aetna and Optum; she now advises companies.

Biopharmaceutical executive and Circular Genomics scientific adviser identified in its dated appointment release as Michael F. Ackermann. His background includes Eli Lilly, Quintiles and Arrivo BioVentures; holds an immunology PhD from Drexel and an MBA from UNC. This identity is preserved separately from the native same-name Vensana/Oculeve medtech adviser.

Circular Genomics cofounder, chief scientific officer and board member whose research focuses on circular RNAs and brain disorders. Previously a tenured associate professor of neuroscience at the University of New Mexico and a postdoctoral researcher at MIT; holds an MD from Athens and a neuroscience PhD from UMass.

President and CEO of Circular Genomics with a career in life-science product development and commercialization across the US, Europe and Asia. Former CEO of Rebus Biosystems; holds a physiology PhD from the University of Cambridge.

Circular Genomics board member with experience developing and commercializing diagnostic products. The company identifies his leadership of Mindera Health and prior CEO role at Exagen.

Scientific adviser to Circular Genomics. Its directory identifies his work at Massachusetts General Hospital’s Center for Experimental Drugs and Diagnostics and his psychiatry professorship at Harvard Medical School.

Chief commercial officer of Circular Genomics with experience commercializing diagnostic and specialty-pharmaceutical products. Previously held leadership roles at Dionysus Digital Health, Biora Therapeutics and Prometheus Laboratories; studied molecular biology and business.

Neurology researcher listed on Circular Genomics’ scientific advisory board. The company identifies his affiliation with Vanderbilt University’s Memory and Alzheimer’s Center.

Diagnostic-assay development professional appointed senior director of clinical research at Circular Genomics in February 2024. Not included in its current published leadership directory; present appointment is unverified.

Tramway Venture Partners managing director and Circular Genomics board member with experience founding healthcare and technology companies. Her company biography describes earlier board roles at MGI Pharma and Health Care Service Corporation, and her PhD and MBA.

Office manager responsible for firm operations. Previously she coordinated national expansion at real-estate startup Side and worked at Corcoran Global Living.

AI lead specialising in model evaluation, fine-tuning and multimodal systems. Previously he led Adobe Firefly text-to-image/video evaluation and post-training. He holds Carnegie Mellon statistics/machine-learning and University of Chicago applied-data-science degrees.

Executive assistant supporting Topher Conway and the firm. Her prior experience includes a family office, Postmates, Twitter and Greenoaks. She holds a psychology degree from Dominican University of California.

Principal with prior investment experience at Insight Partners, TCV and Geodesic Capital, focused on enterprise, infrastructure and application software. He studied economics at the University of Chicago.

Partner and chief operating officer. A former Latham & Watkins corporate attorney, he advised startups, co-founded Cadence Counsel and became A.Capital COO in2014. He holds UCLA and University of Arizona law degrees.

General partner after leading San Francisco seed enterprise investing at General Catalyst during2023–2025. Earlier she led product growth at Amplitude and worked at Lime. She holds Stanford economics and management science/engineering degrees.

General partner leading public policy and communications, including Project Blueprint. His earlier career includes policy/communications leadership at Amazon and Airbnb and service as President Obama’s White House press secretary during2011–2014.

Adam Fazackerley is a general partner at Fortify Ventures and a founder, mentor and investor. His current manager biography describes six US utility patents and additional international patents. It identifies him as chief operating officer of Lay-n-Go, which he co-founded with Amy Fazackerley in 2010, and references the company’s 2022 Inc.5000 recognition. It also describes US Chamber of Commerce Small Business Council work and co-chairing Syracuse University’s library advisory board. These outside affiliations follow the published biography rather than an independently verified current appointment timeline.

Managing partner, joining SV Angel in2009 after business development and sales experience. His published portfolio work includes OpenAI, Hugging Face, Notion, Anduril and TogetherAI. He studied at UCLA.

Ben Herbert is a published &AI adviser, identified as a law-firm partner on its named card. Exact career details and advisory tenure are unpublished.

Caleb Harris is &AI's co-founder and CEO. His self-published Y Combinator biography describes MIT computer-science/neuroscience studies, patent-litigation technical consulting, data-science work at InsideTracker and MIT Media Lab machine-learning research. Exact degree titles and dates are unverified.

Charles Calkins is a published &AI adviser; its card identifies a chemistry and life-sciences leadership function. Exact career details and advisory tenure are unpublished.

Herbert Turner, called Herbie by the company, co-founded &AI and is its CTO. His Y Combinator biography describes MIT aerospace/computer-science studies, autonomous-vessel and machine-learning work, Google language-model fine-tuning and early engineering at Kino AI. Exact degree dates are unpublished.

Jason Mueller is &AI's published intellectual-property litigation adviser, with Vorys named on the adjoining firm card. He is distinct from Adex's Feldera sales executive JasonMueller; the latter's records are preserved. Exact career details and advisory tenure are unpublished.

Josef Schenker is a published &AI adviser, identified as a partner on its named company card. Exact career details and advisory tenure are unpublished.

Peter Magic is a published &AI adviser; the company identifies him as a San Francisco managing partner. Exact career details and advisory tenure are unpublished.

Scott Flanz is a published &AI adviser, identified as a law-firm principal on its named card. Exact career details and advisory tenure are unpublished.

Tigran Guledjian is a published &AI adviser, identified as an intellectual-property litigation co-chair. Exact career details and advisory tenure are unpublished.

Ybet Villacorta is a published &AI adviser, identified as of counsel on its named company card. Exact career details and advisory tenure are unpublished.

Jamie Marraccini is a general partner at Fortify Ventures and an entrepreneur with experience in infrastructure software, inertial navigation and advanced sensing. He co-founded Plesk, which was acquired by SWsoft, later Parallels. The firm’s published career biography describes leadership at Inertial Labs from 2010, the acquisition of MEMSENSE in December2021 and later Inertial Labs acquisition by VIAVI Solutions. Those transaction references describe career history and do not independently establish current subsidiary executive appointments or exact completion dates.

Managing partner of SV Angel with earlier Google and Google Ventures experience and seed investing at Andreessen Horowitz. He founded A.Capital in2014, backing companies including Notion, Hugging Face and Replit, and studied at UCLA. These prior-firm checks are not automatically SV Angel investments.

Simon Rakoff is a general partner at Fortify Ventures. His current biography describes experience as a founder, adviser, board member, angel investor and venture capitalist. It identifies recent consulting for the US Commerce Department on the CHIPS Act and semiconductor manufacturing. He participated in the firm’s historical Fund I as a limited partner and general partner and now focuses on Fund II. Exact appointment dates, educational history and specific personal investment amounts are not disclosed.

Eli Kia is a general partner at Fortify Ventures, overseeing sourcing, diligence, portfolio construction, fund operations and co-investor relationships. His investing focuses on consumer health and human performance. He helps curate the startup programme and investor community for Distilled Intelligence, the firm’s ecosystem summit, and writes the Two and Twenty newsletter about venture-fund legal, regulatory and operational mechanics. His biography describes a Los Angeles upbringing and interests in endurance sport and electronics. A manager role does not establish any personal cash investment.

Wysa develops AI-assisted mental-health support for consumers, employers, insurers and healthcare providers. Its conversational app combines clinician-designed cognitive behavioural exercises, mindfulness and wellbeing tools with access to human coaching and care pathways. Enterprise deployments support referral, between-session engagement and integration with existing benefits and clinical services. Wysa Copilot combines digital exercises, messaging and patient tracking for clinicians. Current services also include collaborative care through April Health and physical therapy through Kins, expanding its combination of digital and human care. The business has operations in Boston, Bengaluru and London; published legal notices identify Touchkin eServices and worldwide affiliates, including Wysa entities, rather than an assumed single-country legal merger. The company publishes research on engagement and outcomes across several settings; these studies do not establish guaranteed benefit for every person or deployment. In May2022, Wysa announced FDA Breakthrough Device Designation for a smartphone conversational CBT agent for adults with chronic musculoskeletal pain and associated depression and anxiety. That designation supports development and review and is not FDA marketing approval. The general wellbeing product is not crisis care or a substitute for medical advice. Public funding includes a USD5.5million Series A announced in May2021, USD20million financing announced in July2022, and a2026 Wellcome-supported GBP5.3million research project for adolescent girls in rural India. The research grant is not equity or unrestricted commercial financing.

Aishwarya Kamath contributes to Wysa’s mental-health technology in the published capacity of AI product contributor (published research; current employment unverified).

Akshat Surolia contributes to Wysa’s mental-health technology in the published capacity of Head of AI.

Anand Gupta contributes to Wysa’s mental-health technology in the published capacity of AI systems contributor (published work; exact current title unverified).

Becky Inkster is publicly identified by Wysa as Adviser. This is an external governance or advisory affiliation.

Chaitali Sinha is publicly identified by Wysa as Chief Clinical R&D Officer. Their published work contributes to the company’s AI and human mental-health support platform.

Charles-Antoine Janssen is publicly identified by Wysa as Board Member. This is an external governance or advisory affiliation.

Dyuthi Dinesh is credited in Wysa’s 2023 Global Employee Mental Health Report for writing and editorial work. Current employment and exact seniority are unverified.

Emma Taylor is publicly identified by Wysa as Children and Young People Clinical Lead & Senior Clinical Safety Officer. Their published work contributes to the company’s AI and human mental-health support platform.

Francesca Baker has a published Wysa affiliation as Published editorial contributor (employment unverified).

Harsh Gupta is publicly identified by Wysa as Deputy CEO & Board Member. Their published work contributes to the company’s AI and human mental-health support platform.

Jo Aggarwal is publicly identified by Wysa as Co-Founder & Chief Executive Officer. Their published work contributes to the company’s AI and human mental-health support platform.

John Tench has a published Wysa affiliation as Published health-systems representative (exact title unverified).

Lila Varsani has a published Wysa affiliation as Chief investigator (published clinical study; current membership unverified).

Madhavi Roy is credited in Wysa’s 2023 Global Employee Mental Health Report for writing and editorial work. Current employment and exact seniority are unverified.

Manish Prajapati contributes to Wysa’s mental-health technology in the published capacity of AI product contributor (published research; current employment unverified).

Technologist and entrepreneur who co-founded LetsVenture, worked at Motorola, Ittiam and Sling Media, and founded pi Ventures. Wysa also publishes him as a board member.

Megan Kirk has a published Wysa affiliation as Published company article author (employment unverified).

Namrata Mayanil contributes to Wysa’s mental-health technology in the published capacity of Engineering Lead.

Nicole Main is publicly identified by Wysa as Clinical Lead. Their published work contributes to the company’s AI and human mental-health support platform.

Poorva Patole is credited in Wysa’s 2023 Global Employee Mental Health Report for marketing and design work. Current employment and exact seniority are unverified.

Pranav Gupta is publicly identified by Wysa as Director, International Partnerships. Their published work contributes to the company’s AI and human mental-health support platform.

Ramakant Vempati is publicly identified by Wysa as Co-Founder & President. Their published work contributes to the company’s AI and human mental-health support platform.

Ross O’Brien has a published Wysa affiliation as Leadership contributor (2023 youth report; current membership unverified).

Sam Leonard is credited in Wysa’s 2023 Global Employee Mental Health Report for marketing and design work. Current employment and exact seniority are unverified.

Sarah Baldry is publicly identified by Wysa as Chief Marketing Officer. Their published work contributes to the company’s AI and human mental-health support platform.

Shakil Imtiaz contributes to Wysa’s mental-health technology in the published capacity of AI research contributor (published work; current employment unverified).

Shubham Mishra contributes to Wysa’s mental-health technology in the published capacity of AI product contributor (published research; current employment unverified).

Shubhankar Sarda is publicly identified by Wysa as Chief Technology Officer. Their published work contributes to the company’s AI and human mental-health support platform.

Siddharth Thakeria is credited in Wysa’s 2023 Global Employee Mental Health Report for writing and editorial work. Current employment and exact seniority are unverified.

Smriti Joshi is publicly identified by Wysa as Chief of Clinical Services and Operations & Board Member. Their published work contributes to the company’s AI and human mental-health support platform.

Vidushi Kamani is publicly identified by Wysa as Board Member. This is an external governance or advisory affiliation.

Vinod Subramanian is publicly identified by Wysa as Head of Compliance. Their published work contributes to the company’s AI and human mental-health support platform.

Jonathon Perrelli is managing partner of Fortify Ventures. He is a founder, investor and operator with more than two decades of experience advising early-stage companies. His current manager biography names an Inertial Labs board position and describes earlier board service at Introhive, the Vinetta Project in Washington, DC, and Document Security Systems. It also describes service with Virginia Tech’s APEX entrepreneurship centre without establishing an appointment date. He founded and served as a general partner of the firm’s historical Fund I. Prior employers and board positions are career history unless explicitly described as current by the source.

Fortify Ventures is a US early-stage venture manager founded in June 2011 to support Washington, DC startups. Its current strategy focuses on technology for consumer health and human performance, investing after a product exists and before product-market fit, commonly at pre-seed or seed. It publishes a USD100,000–2 million typical check range, which is a mandate rather than any company’s actual allocation. The current five-person partnership combines operating and investment experience. Its public portfolio mixes selected historical Fund I holdings and newer Fund II investments, including AI-agent infrastructure and neurotechnology. Fund II is a Delaware limited partnership formed in 2024 with its SEC address in Ashburn, Virginia. Its latest retrieved July 25, 2025 filing reports USD900,000 sold against a USD50 million target; this is an interim subscription disclosure, not a verified final close. Unfinished template office addresses on the website are excluded.

Gabriel Costes is publicly listed by Bpifrance as Retail Funds Development. This affiliation is scoped to Current published retail-funds unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Anne Vinot is publicly listed by Bpifrance as Retail project Manager. This affiliation is scoped to Current published retail-funds unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Caroline Oriola is publicly listed by Bpifrance as Contents and Events Officer. This affiliation is scoped to Current published operating-team unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Caroline Brun Ellefsen is publicly listed by Bpifrance as Sustainability Director. This affiliation is scoped to Current published operating-team unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Antonin Cobolet is publicly listed by Bpifrance as Strategic Investor Program Officer. This affiliation is scoped to Current published operating-team unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Teodora Ene is publicly listed by Bpifrance as Investors Partnerships Director. This affiliation is scoped to Current published operating-team unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Brendan Lanoé is publicly listed by Bpifrance as GP Support Manager. This affiliation is scoped to Current published operating-team unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Martin Naturel is publicly listed by Bpifrance as GP support Officer. This affiliation is scoped to Current published operating-team unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Lisa Coti is publicly listed by Bpifrance as Analyst. This affiliation is scoped to Current published regional-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Antoine Herisset is publicly listed by Bpifrance as Associate. This affiliation is scoped to Current published regional-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Eduardo Sempaio is publicly listed by Bpifrance as Senior Investment Director. This affiliation is scoped to Current published regional-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Sandra Goussu is publicly listed by Bpifrance as Senior Investment Director. This affiliation is scoped to Current published regional-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Alicia Boisseau is publicly listed by Bpifrance as Analyst. This affiliation is scoped to Current published small-cap-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Martin Piechaczyk is publicly listed by Bpifrance as Analyst. This affiliation is scoped to Current published small-cap-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Pierre Bardy is publicly listed by Bpifrance as Analyst. This affiliation is scoped to Current published small-cap-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Esther Cahen is publicly listed by Bpifrance as Analyst. This affiliation is scoped to Current published small-cap-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Justine Palluat de Besset is publicly listed by Bpifrance as Investment Director. This affiliation is scoped to Current published small-cap-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Lucas Bailliart is publicly listed by Bpifrance as Senior Associate. This affiliation is scoped to Current published small-cap-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Nils Laurent is publicly listed by Bpifrance as Investment Director. This affiliation is scoped to Current published small-cap-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Géraldine Fiani is publicly listed by Bpifrance as Senior Investment Director. This affiliation is scoped to Current published small-cap-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Cédric Cabarrus is publicly listed by Bpifrance as Senior Investment Director. This affiliation is scoped to Current published small-cap-funds-investments unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Paul de Lauriston is publicly listed by Bpifrance as Analyst. This affiliation is scoped to Current published vc-growth-funds unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Noor Rabah is publicly listed by Bpifrance as Analyst. This affiliation is scoped to Current published vc-growth-funds unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Kenza Zebdani is publicly listed by Bpifrance as Associate. This affiliation is scoped to Current published vc-growth-funds unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Marine Le Lan is publicly listed by Bpifrance as Associate. This affiliation is scoped to Current published vc-growth-funds unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Timothée Mas is publicly listed by Bpifrance as Associate. This affiliation is scoped to Current published vc-growth-funds unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Claudia Gray is publicly listed by Bpifrance as Associate. This affiliation is scoped to Current published vc-growth-funds unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Mathias Lebouvier is publicly listed by Bpifrance as Senior Associate. This affiliation is scoped to Current published vc-growth-funds unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Adam Chour is publicly listed by Bpifrance as Senior Investment Director. This affiliation is scoped to Current published vc-growth-funds unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Anne Germain is publicly listed by Bpifrance as Senior Investment Director. This affiliation is scoped to Current published vc-growth-funds unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Maud Richecoeur is publicly listed by Bpifrance as Digital Acceleration Manager. This affiliation is scoped to Current published Funds of funds management/digital unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Nina Thigpen is published by Samphire Neuroscience as Nina Thigpen, PhD Ex-Oura, Data Expert. The company lists this affiliation within its scientific-adviser and key-collaborator group, not its statutory board.

Rodrigo Pegado is published by Samphire Neuroscience as Prof Rodrigo Pegado UFRN, Chronic Pain Expert. The company lists this affiliation within its scientific-adviser and key-collaborator group, not its statutory board.

Thomas Rocher is publicly listed by Bpifrance as Digital Transformation Director. This affiliation is scoped to Current published Funds of funds management/digital unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Gorka Gonzalez is publicly listed by Bpifrance as Managing Director of Retail Funds. This affiliation is scoped to Current published Funds of funds management/digital unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Marianne Wlassewitch is publicly listed by Bpifrance as Managing Director of the Operating team. This affiliation is scoped to Current published Funds of funds management/digital unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Barts Charity is an independent London charitable company funding health research and improvements to healthcare for people in East London. The exact legal entity is Barts Charity, Companies House07168381, and registered charity212563. The corporate vehicle was incorporated February24,2010; its charitable registration and predecessor hospital-charity history predate that legal company, so no2010 origin is asserted for the institution. Previous legal names include Barts and the London Charity Trustee and related charities. It is distinct from Barts Health NHS Trust, Queen Mary University of London and the separate St Bartholomew’s Hospital Charitable Fund. The principal charitable purpose is health advancement through organisational grants, research fellowships, clinical research, healthcare innovation and patient experience. Its current own public rosters identify62 people across five senior managers, ten trustees,12 other non-executive committee members and35 additional grant-panel advisers; Sarah Purdy also chairs a panel, yielding63 documented roles. Authentic own portraits are available for27 managers, trustees and non-executives, while35 additional panel biographies publish professional affiliations without portraits. Advisory roles are not employee positions or personal investment checks. The charity manages an endowment supporting grant making; official FY2025 income, expenditure and long-term investments are accounting totals, not LP fund closings or company allocations. Special Purpose Funds and grant schemes are charitable designations rather than verified venture funds. No external-LP fund vehicle or actual capital raise is established. A2019 issuer announcement identifies a joint GBP489,000 translational-research award to ResoTher Pharma and Professor Mauro Perretti’s group at Queen Mary’s William Harvey Institute for preclinical RTP026 work. The company’s allocated share, payment schedule and amount received are unpublished; the joint programme value is not attributed wholly to the company. The institutional grant link is represented separately with issuer-specific cash unknown. Its own current breast-cancer research page explicitly connects its support to the development of PharosAI, using curated NHS data to develop and test clinical AI tools. Historical own reporting also documents brain-tumour translational research and neurosurgical imaging support. These are charitable research programmes; no direct PharosAI equity participation or corporate ticket is inferred.

Ajit Abraham is named in Barts Charity’s current Healthcare Funding Advisory Panel. The own directory identifies the professional affiliation as: Group Director of Inclusion and Consultant Surgeon, Barts Health NHS Trust. This advisory role supports grant review rather than a personal company investment.

Ayo Ajayi is publicly affiliated with Barts Charity. Ayo serves on Finance and Audit. A chartered accountant and risk-governance specialist, she formerly led Anglo American risk and assurance and worked in Deloitte risk consulting.

Catherine Godson is publicly affiliated with Barts Charity. Catherine serves as a trustee and grant-committee member. She is UCD Professor of Molecular Medicine and leads diabetes-complication research at the Conway Institute. Her published background includes Irish and European research governance and UCD innovation leadership.

Charlotte Sparrow is named in Barts Charity’s current Everyday Impact Advisory Panel. The own directory identifies the professional affiliation as: Head of Finance, Whipps Cross Hospital. This advisory role supports grant review rather than a personal company investment.

Claire Davis is named in Barts Charity’s current Everyday Impact Advisory Panel. The own directory identifies the professional affiliation as: Wellbeing Lead, Whipps Cross Hospital. This advisory role supports grant review rather than a personal company investment.

Claire Wells is named in Barts Charity’s current Scientific Review Panel. The own directory identifies the professional affiliation as: Professor in Cancer Cell Biology, King's College London. This advisory role supports grant review rather than a personal company investment.

Craig Finch is named in Barts Charity’s current Everyday Impact Advisory Panel. The own directory identifies the professional affiliation as: Head of Finance, The Royal London Hospital and Mile End Hospital. This advisory role supports grant review rather than a personal company investment.

Daniel Phillips is named in Barts Charity’s current Healthcare Funding Advisory Panel. The own directory identifies the professional affiliation as: Director of Clinical Systems, Barts Health NHS Trust. This advisory role supports grant review rather than a personal company investment.

Davoud Amel-Azizpour is publicly affiliated with Barts Charity. Davoud is a trustee and Finance and Audit Committee chair-elect. He leads Colliers in EMEA after earlier KPMG, RELX and DTZ roles.

Elizabeth Sapey is publicly affiliated with Barts Charity. Elizabeth serves on the Grants Committee. A Birmingham professor and practising respiratory and acute-medicine clinician, she works on translational and data-enabled research and founded the PIONEER acute-care data hub.

Emma English is named in Barts Charity’s current Fellowship Panel. The own directory identifies the professional affiliation as: Associate Teaching Professor in Medical and Health Sciences, University of Cambridge. This advisory role supports grant review rather than a personal company investment.

Ertan Saridogan is published by Samphire Neuroscience as Prof Ertan Saridogan UCLH, Endometriosis Expert. The company lists this affiliation within its scientific-adviser and key-collaborator group, not its statutory board.

Fiona Bickley is publicly affiliated with Barts Charity. Fiona is Chief Operating Officer, overseeing organisational culture, legal and governance, digital systems and delivery. Previously a charity lawyer and British Red Cross in-house counsel, she also holds charitable governance appointments at the London Community Foundation and Royal College of Nursing Foundation.

Fiona Miller Smith is publicly affiliated with Barts Charity. Fiona is Chief Executive, responsible for the charity’s strategy and endowment risk, liquidity and returns. She previously worked in investment banking and private equity, led growth businesses and served as Social Finance director and COO. Her charity biography identifies Baronsmead Venture Trust and Lifting Limits chairmanships.

Frances Prenn is publicly affiliated with Barts Charity. Frances is a trustee and Korn Ferry UK vice-chair. Her work concerns leadership partnerships across philanthropy, government and culture in Britain and the United States. The charity names several additional arts and foundation advisory appointments.

Guang Yang is named in Barts Charity’s current Scientific Review Panel. The own directory identifies the professional affiliation as: Associate Professor Bioengineering, Imperial College London. This advisory role supports grant review rather than a personal company investment.

Guy Lloyd is named in Barts Charity’s current Healthcare Funding Advisory Panel. The own directory identifies the professional affiliation as: Clinical Director of Cardiac Imaging, St Bartholomew’s Hospital. This advisory role supports grant review rather than a personal company investment.

Hannah Young is named in Barts Charity’s current Fellowship Panel. The own directory identifies the professional affiliation as: Associate Professor of Lifestyle as Medicine and Honorary Specialist Physiotherapist, University of Leicester. This advisory role supports grant review rather than a personal company investment.

Hortensia Gimeno is named in Barts Charity’s current Healthcare Funding Advisory Panel. The own directory identifies the professional affiliation as: Associate Director of Research and Clinical Effectiveness for Therapies, Barts Health NHS Trust. This advisory role supports grant review rather than a personal company investment.

Ian Hart is publicly affiliated with Barts Charity. Ian serves as senior independent trustee and chairs the Investment Committee. He is UBS Co-Chair of UK Investment Banking and previously served a three-year secondment as Takeover Panel Director General. His earlier banking employers include Citi and Morgan Stanley.

Ian Jacobs is publicly affiliated with Barts Charity. Ian is an ex-officio trustee through his chairmanship of Barts Health NHS Trust. A cancer surgeon with university leadership experience in Britain and Australia, including Queen Mary, he founded the Eve Appeal and has a Cambridge University NHS Trust non-executive appointment.

Jahanara Ahmed is named in Barts Charity’s current Everyday Impact Advisory Panel. The own directory identifies the professional affiliation as: Portfolio Director to the Group Chief Medical Officer and Group Chief Nurse, Cross Trust. This advisory role supports grant review rather than a personal company investment.

James Peters is named in Barts Charity’s current Fellowship Panel. The own directory identifies the professional affiliation as: Clinical Associate Professor in Rheumatology, Department of Immunology and Inflammation, Imperial College London. This advisory role supports grant review rather than a personal company investment.

Jay Longworth is publicly affiliated with Barts Charity. Jay directs fundraising and communications. She joined from Murray Edwards College Cambridge after earlier senior roles at Imperial College London, the University of Melbourne and World Vision Australia. Her work covers philanthropy, campaigns and research partnerships.

Jean Murphy is publicly affiliated with Barts Charity. Jean is a trustee and Investment Committee member. Her career covers wealth management at Goldman Sachs, ACPI and Morgan Stanley, followed by her own investment-advisory business. The charity also identifies an investment-committee role at Jesus College Cambridge.

Jean-René Jégou is publicly listed by Bpifrance as Managing Director of Regional Funds Investments. This affiliation is scoped to Current published Funds of funds management/digital unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Joyce Yeung is named in Barts Charity’s current Scientific Review Panel. The own directory identifies the professional affiliation as: Professor of Anaesthesia and Critical Care, University of Warwick. This advisory role supports grant review rather than a personal company investment.

Julian Sinclair is publicly affiliated with Barts Charity. Julian serves on the Investment Committee. He previously held chief-investment-officer responsibilities at Macdoch Asset Management and Talisman Global Asset Management and has a Hosking Partners supervisory-board appointment.

Kanchan Rege Thrasher is publicly affiliated with Barts Charity. Kanchan contributes to the Grants Committee. She is an associate medical director at North West Anglia NHS Foundation Trust and a practising consultant haematologist, with earlier executive responsibilities across medical education, research and health inequalities.

Kath Evans is named in Barts Charity’s current Healthcare Funding Advisory Panel. The own directory identifies the professional affiliation as: Director of Nursing for Babies, Children and Young People, Barts Health NHS Trust and Clinical Lead for Babies, Children and Young People, North East London Integrated Care System. This advisory role supports grant review rather than a personal company investment.

Liat Sarner is named in Barts Charity’s current Healthcare Funding Advisory Panel. The own directory identifies the professional affiliation as: Medical Director, Newham Hospital. This advisory role supports grant review rather than a personal company investment.

Matthew Cook is named in Barts Charity’s current Scientific Review Panel. The own directory identifies the professional affiliation as: Professor of Experimental Medicine, University of Cambridge. This advisory role supports grant review rather than a personal company investment.

Matthew Pickering is named in Barts Charity’s current Scientific Review Panel. The own directory identifies the professional affiliation as: Professor of Rheumatology & Director of the Centre for Inflammatory Disease, Imperial College London. This advisory role supports grant review rather than a personal company investment.

Mirela Delibegovic is publicly affiliated with Barts Charity. Mirela is a Grants Committee member and an Aberdeen pharmacology professor with industrial-engagement and knowledge-transfer responsibilities. Her research examines ageing, nutrition and metabolic disease. Her biography identifies Diabetes UK research-governance responsibilities.

Mohammad Memon is publicly affiliated with Barts Charity. Mohammad serves on Finance and Audit. A chartered accountant, he is Europe Arab Bank COO and executive director after earlier KPMG and EY experience.

Naila Nielsen is publicly affiliated with Barts Charity. Naila serves on Finance and Audit. She leads UBS investment-bank AI and transformation following HSBC operational leadership and Deloitte strategy work. Her education includes an Oxford statistics doctorate and Cambridge machine-learning MSc.

Nancy Whiskin is named in Barts Charity’s current Everyday Impact Advisory Panel. The own directory identifies the professional affiliation as: Head of Volunteering, Barts Health NHS Trust. This advisory role supports grant review rather than a personal company investment.

Natalie Pattison is named in Barts Charity’s current Fellowship Panel. The own directory identifies the professional affiliation as: Professor of Clinical Nursing, Imperial College London. This advisory role supports grant review rather than a personal company investment.

Neil MacDonald is named in Barts Charity’s current Healthcare Funding Advisory Panel. The own directory identifies the professional affiliation as: Deputy Chief Medical Officer for Improvement and Transformation, Barts Health NHS Trust. This advisory role supports grant review rather than a personal company investment.

Nikhil Chandra is publicly affiliated with Barts Charity. Nikhil serves on the Investment Committee. He is OMERS Managing Director and Head of European Credit, with prior McKinsey, Deutsche Bank and Aviva Investors experience.

Nimesh Patel is publicly affiliated with Barts Charity. Nimesh chairs Finance and Audit. His charity biography identifies Spirax Sarco leadership, earlier De Beers finance and Anglo American corporate-finance roles, and prior investment banking at J.P.Morgan and UBS.

Nisreen A Alwan is named in Barts Charity’s current Scientific Review Panel. The own directory identifies the professional affiliation as: Professor of Public Health, University of Southampton. This advisory role supports grant review rather than a personal company investment.

Peter Attrill is named in Barts Charity’s current Everyday Impact Advisory Panel. The own directory identifies the professional affiliation as: Strategy and Wellbeing Lead, St Bartholomew’s Hospital. This advisory role supports grant review rather than a personal company investment.

Prabhakar Sundaresan is publicly affiliated with Barts Charity. Prabhakar is Chief Financial Officer and oversees the endowment. He joined after finance leadership at St Luke’s Hospice and a two-decade Standard Chartered banking career. He moved to the charitable sector in2018 and is Glaucoma UK treasurer.

Rachael Natrajan is named in Barts Charity’s current Scientific Review Panel. The own directory identifies the professional affiliation as: Associate Professor and Reader in Cancer Heterogeneity at The Institute of Cancer Research. This advisory role supports grant review rather than a personal company investment.

Ramesh Arasaradnam is named in Barts Charity’s current Fellowship Panel. The own directory identifies the professional affiliation as: Consultant Gastroenterologist, Warwick Medical School, University of Warwick. This advisory role supports grant review rather than a personal company investment.

Richard Lewis is publicly affiliated with Barts Charity. Richard is a trustee and Finance and Audit Committee member. An independent health-strategy adviser, he formerly led healthcare work as an EY partner and has worked at the King’s Fund and Cabinet Office. He is a Nuffield Trust visiting senior fellow.

Sadia Khan is named in Barts Charity’s current Scientific Review Panel. The own directory identifies the professional affiliation as: Professor of Cardiology, National Heart & Lung Institute, Imperial College London. This advisory role supports grant review rather than a personal company investment.

Salman Razvi is named in Barts Charity’s current Fellowship Panel. The own directory identifies the professional affiliation as: Clinical Senior Lecturer and Consultant Endocrinologist, Newcastle University. This advisory role supports grant review rather than a personal company investment.

Sara Little is named in Barts Charity’s current Everyday Impact Advisory Panel. The own directory identifies the professional affiliation as: Head of Quality and Efficiency, St Bartholomew’s Hospital. This advisory role supports grant review rather than a personal company investment.

Sarah Purdy is publicly affiliated with Barts Charity. Sarah is deputy chair, grants-committee chair and Fellowship Panel chair. She is an emeritus Bristol professor and vice-chair of North Bristol NHS Trust, with previous medical-school and university leadership. A GP, she received an OBE for general-practice services in2022.

Shahida Trayling is named in Barts Charity’s current Healthcare Funding Advisory Panel. The own directory identifies the professional affiliation as: Director of Nursing & Governance, Whipps Cross Hospital. This advisory role supports grant review rather than a personal company investment.

Shera Chok is publicly affiliated with Barts Charity. Shera is a Grants Committee member, GP and Shuri Network founder. Her digital-health work includes NHS England and Department of Health leadership, including NHS Digital chief-medical-officer service. She also has London Ambulance Service and NIHR roles.

Steve Bonnard is publicly affiliated with Barts Charity. Steve, registered as Stephen Bonnard, chairs the charity board. Previously a Bridgepoint Development Capital partner and healthcare investment leader, he has private-market investing experience across the UK and Europe. He is a chartered accountant and CFA charterholder.

Steve Watson is named in Barts Charity’s current Scientific Review Panel. The own directory identifies the professional affiliation as: Professor in Cardiovascular Sciences and Cellular Pharmacology, Birmingham University. This advisory role supports grant review rather than a personal company investment.

Tanya Usher is named in Barts Charity’s current Everyday Impact Advisory Panel. The own directory identifies the professional affiliation as: Wellbeing Lead, The Royal London Hospital and Mile End Hospital. This advisory role supports grant review rather than a personal company investment.

Theodoros Arvanitis is publicly affiliated with Barts Charity. Theodoros serves on the Grants Committee. A Birmingham professor of digital-health technology and medical imaging, he researches biomedical engineering, neuroimaging and clinical-system interoperability. His biography names engineering-school leadership and Digital Health journal editorial responsibilities.

Tom Ellis is named in Barts Charity’s current Everyday Impact Advisory Panel. The own directory identifies the professional affiliation as: Director of Strategy, Newham University Hospital. This advisory role supports grant review rather than a personal company investment.

Tristram Mills is named in Barts Charity’s current Everyday Impact Advisory Panel. The own directory identifies the professional affiliation as: Director of Nursing and Governance, Newham University Hospital. This advisory role supports grant review rather than a personal company investment.

Ultan McDermott is publicly affiliated with Barts Charity. Ultan is a trustee and grants-committee member. AstraZeneca’s chief scientist, he researches cancer drug resistance and functional genomics. He previously worked at the Wellcome Sanger Institute and continues clinical oncology at Addenbrooke’s.

Vass Vassiliou is named in Barts Charity’s current Fellowship Panel. The own directory identifies the professional affiliation as: Clinical Professor of Cardiac Medicine, Norwich Medical School. This advisory role supports grant review rather than a personal company investment.

Victoria King is publicly affiliated with Barts Charity. Victoria directs funding and impact evaluation. She previously led science-strategy delivery at Wellcome, after NIHR research-network and Diabetes UK research leadership. She has a cellular-signalling biochemistry doctorate and chairs Guts UK’s trustees.

Will Riley is publicly affiliated with Barts Charity. Will serves on the Investment Committee. He leads investment solutions at L&G Asset Management for institutional and charitable clients, following BlackRock and Sanlam investment-management work.

Zudin Puthucheary is named in Barts Charity’s current Healthcare Funding Advisory Panel. The own directory identifies the professional affiliation as: Clinical Senior Lecturer, William Harvey Institute, Queen Mary University of London and Consultant in Intensive Care, The Royal London Hospital. This advisory role supports grant review rather than a personal company investment.

Rémi Berteloot is publicly listed by Bpifrance as Managing Director of Small Cap Funds Investments. This affiliation is scoped to Current published Funds of funds management/digital unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Christelle Rogé is publicly listed by Bpifrance as Directrice exécutive Direction des ressources humaines. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Florent Debienne is publicly listed by Bpifrance as Managing Director of Venture & Growth Funds Investments. This affiliation is scoped to Current published Funds of funds management/digital unit; not institution-wide headcount. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Jeffrey Shuren is published by Samphire Neuroscience as Jeffrey Shuren, MD, JD Princeton, Ex-Head of FDA Center for Devices. The company lists this affiliation within its scientific-adviser and key-collaborator group, not its statutory board.

Ieva Karvelytė is published by Samphire Neuroscience as Ieva Karvelytė MSc Research Manager. This role is part of its current core leadership and research team developing non-invasive neurotechnology for menstrual-health symptoms.

Jean-Marie Suquet is publicly listed by Bpifrance as Directeur exécutif Direction des Risques. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Olivier Vincent is publicly listed by Bpifrance as Directeur Exécutif Direction Export. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Julien Noronha is publicly listed by Bpifrance as Directeur Exécutif Direction de la communication. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Kendell Cannon is published by Samphire Neuroscience as Kendell Cannon MD Chief Medical Officer. This role is part of its current core leadership and research team developing non-invasive neurotechnology for menstrual-health symptoms.

Matthieu Heslouin is publicly listed by Bpifrance as Directeur exécutif Direction du Conseil. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Ervinas Bern is published by Samphire Neuroscience as Ervinas Bern MEng CTO. This role is part of its current core leadership and research team developing non-invasive neurotechnology for menstrual-health symptoms. UKRI project10039602 identifies him as Ervinas Bernatavicius, technical/product lead; current directory uses Ervinas Bern.

Adeline Lemaire is publicly listed by Bpifrance as Directrice Exécutive Direction Fonds de fonds. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Alex Cook is published by Samphire Neuroscience as Alex Cook JD COO (Founder). This role is part of its current core leadership and research team developing non-invasive neurotechnology for menstrual-health symptoms. Co-founder with a JD; UKRI calls him Alexander Cook, commercial lead. Primary investor AfterWork’s January2022 thesis describes his Oxford Master’s in Law and Finance, work as a founding team member at Bamboo and technology/intellectual-property legal experience at Herbert Smith Freehills. It states that he joined the AfterWork community in May2021 and worked on regulatory and IP questions. Current company branding lists his JD and co-founder/COO role; these historical career facts do not imply any investor allocation made personally.

Pascal Lagarde is publicly listed by Bpifrance as Directeur Exécutif Direction de l'International, de la Stratégie, des Etudes et du Développement. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Eric Versey is publicly listed by Bpifrance as Directeur exécutif Direction du Financement et du Réseau. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Emilė Radytė is published by Samphire Neuroscience as Emilė Radytė PhD CEO (Founder). This role is part of its current core leadership and research team developing non-invasive neurotechnology for menstrual-health symptoms. Co-founder with a neuroscience PhD; UKRI identifies Emile Radyte as project manager for the company’s clinical and device research. Primary investor AfterWork’s January2022 thesis describes her Oxford doctorate research in neurobiology/neuroscience, modelling deep-brain stimulation for psychiatric applications and neurocognitive biomarkers of response in depression. She previously studied neuroscience and social anthropology at Harvard, graduating summa cum laude; the current company directory confirms her completed PhD and co-founder/CEO role. The company’s own clinician-training page identifies Oxford and Harvard training. Her device company commercialises non-invasive stimulation; prior deep-brain research does not mean its product is an implanted device.

José Gonzalo is publicly listed by Bpifrance as Directeur exécutif Direction du Capital Développement. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Samphire Neuroscience Ltd is a London neurotechnology and medical-device company developing non-invasive brain stimulation for women’s menstrual health, chronic pain and mood conditions. Incorporated in the United Kingdom on September2,2021 under company number13600022, it was formerly The Nucleaire Ltd until February2022. Neuroscientist Emilė Radytė and lawyer Alex Cook co-founded the business. Its technology is transcranial direct current stimulation (tDCS), delivered through the Samphire Headband, originally branded Nettle. This is a neuroscience and medical-hardware platform; no unsupported neural implant or specific AI algorithm is inferred. The company’s current site describes Nettle as a ClassIIa medical device with UK/EU clearance for specific indications and distinguishes the Lutea general-wellness variant. Its footer explicitly states that its products have no US FDA approval or clearance. PMDD, endometriosis, perimenopause and other chronic-pain research and sponsor-reported trial outcomes are not treated as universal cleared indications or independent efficacy guarantees. The device’s targets include motor and prefrontal cortex, relevant to pain and mood. Its complete published current roster has five core leaders and six scientific advisers or clinical collaborators. The collaborator directory is not a statutory board or an inference of personal investment. Original name-bound company portraits and branding are preserved. Primary investor evidence confirms a USD5million seed raise reported in June2025, led by Inventure alongside Fortify Ventures; Fortify’s own portfolio explicitly qualifies its co-lead role. A separate USD2.3million pre-seed round is confirmed by CVX Ventures and the company’s transaction counsel in February/March2024. Exact settlement dates and individual allocations remain unpublished. SOSV’s own portfolio identifies HAX2021 participation, but that does not independently prove its involvement in the2025seed. UKRI reports three InnovateUK grant projects with direct named beneficiary Samphire Neuroscience Ltd: the2022–2024 menstrual-health device project, the2024–2025 Nettle clinical pilot and the2024–2025 SamphireXR perimenopausal insomnia/anxiety project. Awards and funded values are not project costs or verified cash-disbursement dates. A separate SBRI Healthcare PMDD validation award is jointly named with Queen Mary University of London; the consortium amount is not automatically assigned entirely to Samphire. The original2025 post by Fortify’s general partner Eli Kia names additional actual seed participants: APEX Ventures, SOSV, AfterWork Ventures, FIRSTPICK, Ayuh Ventures and Seaside Ventures. Each verified manager is linked once to the existing USD5million seed event, separately from its prior pre-seed relationship. The APEX hyperlink identifies a Portuguese investment brand, verified as APEX Capital, apex-cp.com, under the APEX Cap Group brand and disclosed Luxembourg APEX Elite Management platform. This is distinct from the Austrian APEX namesake. Direct participation evidence supersedes reliance on a generic portfolio page, while individual tickets remain unpublished. Earlier AfterWork and Ayuh accounts describe investments during2022; these may form part of the subsequently reported cumulative pre-seed financing and are not separate fabricated USD2.3million raises.

Paul-François Fournier is publicly listed by Bpifrance as Directeur Exécutif Direction Innovation. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Marie Adeline-Peix is publicly listed by Bpifrance as Directrice Exécutive Direction Partenariats Régionaux, Création et Action Territoriale. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Arnaud Caudoux is publicly listed by Bpifrance as Directeur Exécutif Directeur général adjoint. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Nicolas Dufourcq is publicly listed by Bpifrance as Directeur général de Bpifrance Président-Directeur général de Bpifrance Participations Président de Bpifrance Investissement Président de Bpifrance Assurance Export. This affiliation is scoped to Current own executive committee directory. The institution provides lending, innovation support and investment management; role membership is not a personal financial contribution.

Everbright Health is a US healthcare technology and services business, operated by Careforce Inc., that helps existing mental-health practices add and manage interventional psychiatry services. Its Activate AI platform supports review of clinical records, identification and outreach to potentially eligible patients, scheduling and payer prior-authorization workflows. The company also provides equipment, technical staffing, operational support, billing and compliance infrastructure for services such as transcranial magnetic stimulation (TMS) and SPRAVATO treatment. Its model embeds these service lines within partner practices, including treatment-resistant depression care, rather than manufacturing a drug or stimulation device. Founded by Ben Kuhn and Ginger Holguin and incubated by W Health Ventures/2070 Health, Everbright announced its launch and seed investment in October2025. Its current public leadership includes a psychiatrist serving as Chief Medical Officer.

Alex Weisman is Head of Product at Everbright Health. Known professionally as Alex (Goldy) Weisman, a digital and behavioral-health product leader with experience scaling product portfolios.

Arunsathyaseelan Palanichamy is Head of Enablement at Everbright Health. Known professionally as Arun Palanichamy, a healthcare operator with experience in US health-tech strategy, go-to-market execution and cross-functional operations.

Benjamin Robert Kuhn is Co-Founder and CEO at Everbright Health. Healthcare executive and company builder with experience developing and scaling management-services organizations.

Ginger Holguin is Co-Founder and Head of Operations at Everbright Health. Behavioral-healthcare operator with experience managing multi-clinic interventional psychiatry operations.

John L. Fleming is Chief Medical Officer at Everbright Health. Board-certified psychiatrist and Clinical TMS Society Fellow with extensive clinical experience in interventional psychiatry.

Mollie Brick is Head of Patient Activation at Everbright Health. Patient-access and growth-operations leader who develops activation models and targeted patient-outreach programs.

Tyler Lakin is Head of Commercial at Everbright Health. Healthcare technology and services executive with experience in commercial operations and provider partnerships.

Vlad Laypa is Head of Engineering at Everbright Health. Technology, product, user-experience and data-science leader with experience building and scaling software businesses.

Alexandre Saada (legal full name Alexandre Simon Saada) is a former chair of Banque CIC Ouest. The public BODACC notice published April 18, 2023 identifies his departure as chair and Hervé Bressan as successor. The exact effective departure day has not been established from the archived announcement, so no day is asserted. This documents a historical regional-bank governance affiliation, without inferring a current appointment or personal investment.

Hervé Bressan is identified as chair of Banque CIC Ouest in its 2024 regional publication. The bank’s own April 23, 2025 announcement names Laurent Berger as his successor. His authentic published portrait is extracted from the original embedded image in the 2024 document. His chairmanship is therefore historical, not a current position.

Frédéric Robin is named as Corporate Market Director in Banque CIC Ouest’s own 2024 regional publication, alongside the six-person executive committee. The original named portrait is extracted without alteration from that publication’s embedded bitmap. This documents the published 2024 appointment; an exact current continuation or departure date has not been established, and the affiliation is expressly dated rather than presumed current.

Franck Terrail is named as Private Banking Market Director in Banque CIC Ouest’s own 2024 regional publication, alongside the six-person executive committee. The original named portrait is extracted without alteration from that publication’s embedded bitmap. This documents the published 2024 appointment; an exact current continuation or departure date has not been established, and the affiliation is expressly dated rather than presumed current.

Lise Louvigny is named as Retail Market Director in Banque CIC Ouest’s own 2024 regional publication, alongside the six-person executive committee. The original named portrait is extracted without alteration from that publication’s embedded bitmap. This documents the published 2024 appointment; an exact current continuation or departure date has not been established, and the affiliation is expressly dated rather than presumed current.

Jason Ward is Script and Production Associate at Adeline Arts and Science. Jason is a Glasgow-based writer and film journalist. From 2011 to 2019 he contributed to Oh Comely magazine as its associate editor, and his work has appeared in publications including The Guardian, Little White Lies and Dazed. Jason is the author of several non-fiction books, including A Year of Good Things, and has contributed to books including Movie Star Chronicles and 1001 Movies You Must See Before You Die. He has recently completed an MSc in Film Curation at the University of Glasgow. Source scope: current own public biography, exact appointment day not published.

Lamia Goura is named as Director of Resources in Banque CIC Ouest’s own 2024 regional publication, alongside the six-person executive committee. The original named portrait is extracted without alteration from that publication’s embedded bitmap. This documents the published 2024 appointment; an exact current continuation or departure date has not been established, and the affiliation is expressly dated rather than presumed current.

Andrea Puma is Facilities Manager at Adeline Arts and Science. Andrea is our facilities manager and interior designer, specialising in commercial facilities. She curates the nature-inspired aesthetic of Adeline’s studio and creates a calm and welcoming space for the team, our Founders’ Floor members and everyone who uses the building. She started working for Heal’s and Selfridges, then moved to Westfield and worked her way up to the facilities department. She is passionate about interior design, with a degree in furniture and product design, and more recently completed an interior design course with the Interior Design Institute. Source scope: current own public biography, exact appointment day not published.

Meerab Baig is Platform Associate at Adeline Arts and Science. Meerab is the organising force behind Adeline. She keeps the team current and connected, staying abreast of the latest events and research, aligning diaries and bringing people together with an infectious energy. She has previously dedicated her time to research, customer service, and charitable campaigns, such as UP’s Support Well project informing strategies for adults with cerebral palsy. She is adept at document management, client-facing duties, inventory keeping, and Microsoft Office. Out of hours, Meerab likes to spend her time rating restaurants, watching movies, and you’ll rarely see her missing a Formula One race. Source scope: current own public biography, exact appointment day not published.

Olivier Marcelin is named as Director of Credit Commitments in Banque CIC Ouest’s own 2024 regional publication, alongside the six-person executive committee. The original named portrait is extracted without alteration from that publication’s embedded bitmap. This documents the published 2024 appointment; an exact current continuation or departure date has not been established, and the affiliation is expressly dated rather than presumed current.

Laurence Carde, registered with full legal name Laurence Isabelle Carde, was designated on April 16, 2026 as the permanent representative of corporate director Crédit Industriel et Commercial on the Banque CIC Ouest board, succeeding Isabelle Pitto. This represents the corporate director’s seat and is not presented as a separate independent director appointment. The issuer legal notice published April 30, 2026 and BODACC notice of May 31, 2026 corroborate the appointment.

Liz Ann Bennett is VP of Operations and Strategy at Adeline Arts and Science. Liz started her career publishing Oh Comely magazine, an artbook-style bimonthly that catalysed a new wave of independent women’s media. As a senior content strategist at DNCO and other agencies, she spent the best part of a decade helping places find their edge amid transformation. Now, she is Adeline’s champion of clarity, bringing concision and coherence both operationally and to the fund’s strategy. Out of hours, you’ll find Liz where nature and community intersect, volunteering as chair of the Friends group for her local park, a role that includes organising an annual skatejam and music festival for teens. Source scope: current own public biography, exact appointment day not published.

Theo Brainin is VP of Growth and Marketing at Adeline Arts and Science. Theo has helped to shape Adeline since its early days, and now leads growth and marketing for the family office and our portfolio. He has 10+ years' experience helping startups grow, from consumer and SaaS to health tech. Along the way he has played a key role at two companies as they scaled revenues 7x and 10x, and has successfully pitched angels, crowds and even some dragons. He holds a First in PPE and an MPhil in Political Theory from Oxford. Outside of work he enjoys playing guitar and photography. Source scope: current own public biography, exact appointment day not published.

Lone Veng, also identified as Lone Merete Veng in her original2022 interview, is the former CEO of ResoTher Pharma. The issuer’sFebruary1,2023 leadership announcement confirms she led the business since2017 and handed leadership to AndersKronborg, effectiveFebruary1,2023. She led earlypreclinicaldevelopment, researchgrantfunding, theMay2021DKK38.8M private shareissue and first-in-human clinicaldevelopment ofRTP026. The originalOctober25,2022 companyinterview provides an authentic explicitlycaptioned companyportrait. Her role is historical rather than current2026 employment or a personalinvestment.

Anthony Mathur is a clinical cardiologist and the Clinical Director for Interventional Cardiology at BartsHeartCentre. The own ResoTher scientific advisory directory lists him as an external scientific adviser. QueenMaryUniversity’s own biography identifies him as CentreLead for CardiovascularMedicineandDevices, leading the cardiovascular devices hub and translational research into biologics, advanced cardiac imaging and interventional treatments. His advisory role is distinct from a companyemployee or personalinvestment. The issuer image is a placeholder and the genuine institutionalportrait returned403/404; no fakeimage is attached.

Jaysri Thangam Ananthpadmanabhan is Investment Principal at Adeline Arts and Science. Jaysri is an early-stage investor and operator specialising in startups across UK and DACH. An electronics engineer by background, Jaysri was part of the founding teams at two fintech startups in India, where she helped scale operations, drive revenue growth, and launch products from zero to market. This hands-on operator experience shapes her investment approach, balancing conviction in bold ideas with a focus on strong business fundamentals. At Adeline, Jaysri focuses on sourcing and evaluating early-stage opportunities across the UK and Europe. A true generalist, she is drawn to outlier founders that are ever curious, and have a systems approach to building products that make life and the world better. Source scope: current own public biography, exact appointment day not published.

Des Tan is Founder & Director at Adeline Arts and Science. Des Tan studied mathematical biology at Oxford where he worked on population modelling and infectious-disease modelling of malaria, bubonic plague and other zoonoses. Des was an advisor and tech lead for the Prime Minister's Strategy Division in Australia, analysing census and other population data to build strategic frameworks, economic models and decision-support tools. Des’s current work involves building data models, analytics platforms and web-based tools for government, the UN, FTSE 100 companies and digital health services. His main interest is in healthcare and health technology, and genuine human needs that are overlooked and underserved. Source scope: current own public biography, exact appointment day not published. Published Des Tan differs statutory Derek Tan; legal-name bridge unproven, so no registry date or legal alias inferred.

Jacques Barillet was co-opted to the Banque CIC Ouest board on September 18, 2025, replacing Hervé Bressan. An issuer legal notice published September 16, 2026 reports his resignation by letter dated September 9, 2026. The government register still lists him as a director, so the later explicit resignation is retained and this affiliation is historical.

Oliver Soehnlein, MD / PhD Dr. Soehnlein is Professor of Regulatory Mechanisms of Inflammation and Director of the Institute of Experimental Pathology (ExPat) at the University Hospital in Münster, Germany. He obtained is MD from the University of Erlangen (Germany) and his PhD from the Karolinska Institute in Stockholm (Sweden). Oliver Soehnlein has made several inventions aimed at controlling excessive inflammation and his research focuses on myeloid cell driven inflammation and its resolution in the field of cardiovascular pathologies. His seminal studies are published in leading journals including Nature, Circulation, and Science Translational Medicine.

Adeline is the London family office operating adeline.co.uk and publicly identifying its operator as Adeline Arts & Science Ltd. The exact UK legal company is ADELINE ARTS AND SCIENCE LTD, Companies House13110623, active and incorporated January4,2021, with registered office116HighHolborn,ThirdFloor,LondonWC1V6RD, matching the own contact address. The incorporation year is not an invented earlier investment-platform founding date. The own website explicitly says it is not FCA-authorised or regulated, offers no investment advisory services and does not solicit investment from the general public. It is kept distinct from unrelated Adeline-named businesses and from third-party investment firms listed in its educational investor directory. That directory is not Adeline’s own team, managed-fund list or co-investor graph. The family office backs pre-seed through SeriesA technology companies and follows on, with a published average cheque of GBP150K and a five-to-ten-year investment horizon. These are strategy parameters, not amounts assigned to particular portfolio companies. Its mandate spans frontier technology, infrastructure, AI, deep science, climate and health, alongside film, publishing and scientific-research support. The no-fees/no-equity Founders’ Floor provides workspace, community and workshops; membership is not an equity subscription. No external-LP fund, closed fundraising cash, AUM or government programme budget is established. Own calls itself a family office; loose uses of “fund” do not prove a separate legal fund vehicle. The complete own published team comprises Des Tan (Founder & Director), Jaysri “Jay” Thangam Ananthpadmanabhan (Investment Principal), Liz Ann Bennett (VP of Operations and Strategy), Theo Brainin (VP of Growth and Marketing), Meerab Baig (Platform Associate), Andrea Puma (Facilities Manager) and Jason Ward (Script and Production Associate). All seven have individually identified original authentic portraits and meaningful own-source career biographies. Des’s biography covers Oxford mathematical biology, Australian governmental strategy, and analytics/digital health. The statutory Companies House director is filed as Derek Tan, while the own public team uses Des Tan; the possible name bridge is not independently established, so no legal-name alias, birth date or registry appointment day is silently attached to the public person. Public roles and appointment dates remain source-qualified. Own “portfolio and partners” includes AI investment-workflow company Capsa AI, AI manufacturing company CloudNC, secure enterprise AI-agent platform Credal, AI ophthalmic-genetics company Eye2Gene, infection-prevention AI platform NEX Health Intelligence, sodium-battery innovator TaiSan, stellarator developer Proxima Fusion, agentic-payments platform Ralio and critical-pharmaceutical infrastructure company Genhtis. It also includes universities, charities, research institutes, scholarships, arts organisations and third-party funds; this heterogeneous relationship category is not assumed to consist entirely of equity checks. Stage tags are descriptive page classifications, not proof of an exact closed round date or subscriber allocation. A total of29 own directory affiliations are queued for scoped identity and transaction audits, with relevant AI/deeptech companies prioritised. Eye2Gene’s own current supporter directory links exactly to Adeline, and Adeline’s own portfolio names Eye2Gene as an AI/health Seed-stage company. Together these establish a public portfolio/support relationship. They do not identify the buyer of Eye2Gene’s unnamed statutory share allotments, a particular subscribed security, cash ticket, funding date or specific seed financing event. The issuer-profile owner records exactly one source-qualified undated relationship with unknown amount; no duplicate personal founder check, programme buyer or guessedGBP150K ticket is inferred. Other issuer actual cash events require separate primary financing proof before graph additions.

Mauro Perretti, PhD Dr. Perretti is Professor of Immuno Pharmacology at Queen Mary University, London and Dean of Research, Barts and the London School of Medicine. Professor Perretti has several inventions in the field of FPR2-agonists, including co-inventions of several of ResoTher Pharma´s lead compounds. He is a renowned scientist and has published extensively on the role of the naturally occurring peptide Annexin A1 in the resolution of inflammation. Professor Perrettti is the author of more than 300 highly cited publications and is a fellow at the British Pharmacological Society.

Rod Flower, Prof. Emer. DIRECTOR Dr. Flower, a distinguished pharmacologist, graduated with first-class honors in physiology from the University of Sheffield in 1971. After postgraduate training with Nobel Laureate John Vane, he spent over a decade at the Wellcome Foundation before becoming the Chair of Pharmacology at the University of Bath in 1985. He is the co-founder of the William Harvey Research Institute and was Institute Director from 2000-2004. Dr. Flower made significant contributions to understanding the biology of annexins and their anti-inflammatory properties and has published over 350 papers and books. He has received numerous national and international awards, including the 2005 Lifetime Achievement Award from the International Association of Inflammation Societies.

Stéphanie Le Donge is registered as a natural-person director of Banque CIC Ouest in the French government business register reviewed October 8, 2026, with RNE data updated September 26, 2026. This is the regional bank with SIREN855801072, rather than membership of the separate parent CIC board. No broader employer biography or personal financial participation is inferred from the statutory appointment.

Michael Østerlund Madsen is a publicly named director of ResoTher Pharma on its current own board page, with an original caption-bound portrait. The company states his fuller biography is forthcoming; priorcareer, investmentallocation andstartday are not inferred. The role is companygovernance, not assumed fulltimeemployment.

Sven Jacobson, MBA DIRECTOR Sven Jacobson is a life science entrepreneur. He has co-founded and serves as CEO of Woolsey Pharmaceuticals, a privately held, clinical stage pharmaceutical company. Previously, Mr. Jacobson co-founded and served on the board of Access Scientific, Cure Therapeutics and St. Camillus Medical and is currently a Director of the Board of Critical Diagnostics and a Partner at Carrot Capital Healthcare Ventures

Henrik Stage, MS DIRECTOR Henrik Stage has held roles such as VP, CFO, and CEO in a number of successful international corporations, including Carlsberg Breweries, Hempel Intl, and Santaris Pharma. At Santaris Mr. Stage served as CEO and CFO and closed partnerships with Pfizer, Wyeth, Shire, GlaxoSmithKline and managed the sale and asset transfer to Roche. Currently Mr. Stage serves as CFO at RhoVac and SynAct Pharma.

Jeppe Øvli Øvlesen, MBA DIRECTOR Jeppe Øvlesen is an experienced biotech entrepreneur and has been involved as founder/CEO/Chairman in a string of successful companies including Action Pharma, CLC Bio, Cetrea, ChemoMetec, Monsenso, PNN Medical, and TXP Pharma. Mr. Øvlesen is co-founder and presently serves as CEO of SynAct Pharma, which is listed on Nasdaq Stockholm.

François Marie Feuillet is registered as a natural-person director of Banque CIC Ouest in the French government business register reviewed October 8, 2026, with RNE data updated September 26, 2026. This is the regional bank with SIREN855801072, rather than membership of the separate parent CIC board. No broader employer biography or personal financial participation is inferred from the statutory appointment.

Thomas Jonassen, MD, DIRECTOR Thomas Jonassen is an experienced biotech entrepreneur, having founded a number of successful biotech companies. He is the former co-founder and Chief Science Officer of Action Pharma (sold to Abbvie in 2012), TXP-Pharma (main asset sold to Questcor Pharmaceuticals in 2015) and presently also serves as CSO at SynAct Pharma, a biotech company focused on novel therapeutics for inflammatory joint disorders. In addition to these roles, Dr. Jonassen is associate professor at the University of Copenhagen in the department of Cardiovascular Pharmacology and an honorary professor at William Harvey Research Institute at the Queen Mary University in London.

Becki Morison CHAIR Becki Morison is a seasoned leadership profile with strong US pharma and international experience, mainly in the fields of commercial product strategy and business development. In addition, she has a proven track record in building and growing innovative pharmaceutical businesses. Becki has spent +20 years with Eli Lilly, holding senior positions within international market access, Business Development and Commercialization. Most recently she has been Executive Vice President, Global Strategy and International Operations at LEO Pharma. Becki was elected to the board in September 2025 and subsequently took over as new Chairman.

Morten Lind Jensen, MD, PhD. CHIEF MEDICAL OFFICER Morten Lind Jensen has broad experience with clinical product development leadership from positions in both biotech and pharma companies. Before joining ResoTher, Morten was CMO in Union Therapeutics, a private scale-up biotech company. Prior to that, he spent almost 10 years in Novo Nordisk, spanning roles as medical specialist, project manager and line manager, where he has worked across the internal product portfolio and established external collaboration projects within new ways of doing clinical trials and using data. Morten is MD with a PhD from University of Copenhagen, Denmark and he holds a Diploma in Pharmaceutical Medicine from the Royal Colleges of Physicians of the United Kingdom.

Valérie Estrade is registered as a natural-person director of Banque CIC Ouest in the French government business register reviewed October 8, 2026, with RNE data updated September 26, 2026. This is the regional bank with SIREN855801072, rather than membership of the separate parent CIC board. No broader employer biography or personal financial participation is inferred from the statutory appointment.

Hanne Vissing Leth, M.Sc. CHIEF FINANCIAL OFFICER Hanne Vissing Leth is a finance executive with broad experience across disciplines of Finance, Funding, Investor Relations and Corporate Governance. Hanne’s career has been focused on the Life Science sector and she has held senior leadership positions in both public and private biotech and medtech companies. She has also worked for more than 10 years in investment banking and equity research. Hanne holds a Master’s degree in Business Administration and International Finance from the Aarhus School of Business and Social Sciences and has a certificate of Board Leadership from Copenhagen Business School Executive.

Marie-Astrid Sevilla is named in Angels Santé’s own current roster as Angels Santé USA — Boston representative. This is a Boston representative of the network’s US branch, not proof of a separate US employer or investment entity. Complete earlier career, education and exact appointment dates are not published in the accessible own roster; personal cash investments are not inferred from membership or board service.

Anders Kronborg, M.Sc. CHIEF EXECUTIVE OFFICER Mr Kronborg is a seasoned executive with more than 25 years experience as CEO, CFO or COO. After he graduated as economist from Copenhagen University he spent 7 years in different roles in the ministry of Finance. From 2007-2015 Mr Kronborg worked for Kinnevik – a Swedish investment company listed in Stockholm – from 2012-2015 as COO for the whole group,  getting private companies ready to go public and listing them together with other investors. More recently (2015-2022) Mr Kronborg was CFO and interim CEO in LEO Pharma – a global Pharma company specialized in skin diseases.

Alain Pierre Boye is registered as a natural-person director of Banque CIC Ouest in the French government business register reviewed October 8, 2026, with RNE data updated September 26, 2026. This is the regional bank with SIREN855801072, rather than membership of the separate parent CIC board. No broader employer biography or personal financial participation is inferred from the statutory appointment.

ResoTher Pharma is a Danish clinical-stage biotechnology company developing peptide-based resolution therapies to modulate inflammatory responses in acute cardiovascular disease. Its exact legal entity is ResoTher Pharma A/S, CVR37852406, formerly styled ApS in historical financing announcements, based in Holte nearCopenhagen. Its lead investigational compound RTP-026 is an AnnexinA1-derived FPR2 agonist being studied as a potential cardioprotective treatment in patients with acute myocardial infarction; issuer-reported2026Phase2a findings are research results, not regulatory approval or established clinical effectiveness. The scientific programme originates in research at the WilliamHarveyResearchInstitute and QueenMaryUniversityofLondon. This is deep biotechnology/drug-development coverage; direct AIsoftware or neuroscience product claims are not established. Current own public management names CEOAndersKronborg, CFOHanneVissingLeth and CMOMortenLindJensen. The published board includes chairBeckiMorison, ThomasJonassen, JeppeØvliØvlesen, HenrikStage, MichaelØsterlundMadsen, SvenJacobson and RoderickFlower. External scientific advisers are distinguished from employees; ThomasJonassen is also explicitly listed asChiefScienceOfficer. Co-foundersThomasJonassen andJeppeØvlesen’s2017CSO/CFO roles and formerCEOLoneVeng are historical; old leadership posts are not used to overwrite current2026 management. A2017seed financing signed withCAPNOVA aslead has undisclosed cash amount; the November2019DKK16.5M combined financing comprises equity and three grants, so it is not entered as pure equity or additional cash on topof its grant components. A completedMay2021share issue raisedDKK38.8M. ExactEUproject grants and received advances are distinguished from roundedawardannouncements and are not duplicated. The2024signedannualreport provides legalidentity and historicalfunding evidence, while2025plannedshareissuance commitments are not assumed cashcloses. HunterCapitalRTO1’s March2026 reverse-takeover LetterofIntent remained an intended all-share transaction: itsSeptember30,2026 announcement extends theLOI throughDecember31,2026. ResoTher separately completedapproximatelySEK14.8M bridgefinancing announcedJuly6,2026; no investor allocation or plannedlargerRTO financing/valuation is inferred as paid issuer cash. No completed public listing or merger withHunter is asserted.

David Setboun is named in Angels Santé’s own current roster as Angels Santé USA — Boston representative. This is a Boston representative of the network’s US branch, not proof of a separate US employer or investment entity. Complete earlier career, education and exact appointment dates are not published in the accessible own roster; personal cash investments are not inferred from membership or board service.